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1. Abstract
Background:  Fibroblast growth factors 1 and 2 (FGF–1 and FGF–2), potent
mitogens for endothelial cells and vascular smooth cells, are implicated in
arterial and capillary growth as well as in cardioprotection.  Monocyte
chemoattractant protein 1 (MCP–1) is involved in various inflammatory
conditions. Utilizing transgenic mice (TG) overexpressing FGF–1, FGF–2, or
MCP–1 and nontransgenic controls (NTG), the effects of these factors on vascular
development, cellular protection, cardiac performance, and exercise tolerance
were studied.
Methods:  1. Ventricular cardiac myocytes of hearts of FGF–1 TG and NTG were
isolated and submitted to simulated ischemia and reoxygenation.  The releases of
CK and LDH were quantified.  2. The coronary flow of the hearts of FGF–1 TG
and NTG was quantified utilizing ex vivo retrograde perfusion under maximal
vasodilation at four different pressures.  3. Right femoral arteries of FGF–2 TG
and NTG were occluded.  Mice were assigned to a sedentary or a trained group.
After 5 weeks, collateral dependent blood flows to the foot and to the
gastrocnemius muscle were determined.  Exercise capacity was accessed,
postmortem angiograms and histomorphometry of collateral arteries were
performed.  4. Exercise tolerance of MCP–1 TG and NTG was determined by
graded exercise tests over a period of four months.  5. The relationship between
recovery of exercise capacity and increase in collateral dependent blood flow after
bilateral femoral artery occlusion was investigated in three different mouse
strains.
Results:  1. CK and LDH release of myocytes of FGF–1 TG was reduced at 4h
and 8h of simulated ischemia.  2. The pressure dependent increase in coronary
flow was markedly elevated in hearts of FGF–1 TG.  3. Foot and gastrocnemius
blood flows as well as exercise capacity were increased in trained FGF–2 TG that
showed the formation of a dense collateral network.  4. Exercise tolerance of
MCP–1 TG was markedly reduced.  5. Increased collateral dependent foot blood
flow is only partially reflected by the recovery of exercise capacity.
Conclusions:  Cardiac-specific FGF–1 overexpression protects ventricular
myocytes against simulated ischemia and increases coronary flow.  General
FGF–2 overexpression and training enhance the formation of a dense collateral
network, increase collateral dependent blood flow and exercise capacity.  Cardiac-
specific MCP–1 overexpression induces myocarditis and causes exercise
intolerance as a typical symptom of congestive heart failure.  Recovery of
collateral dependent resting blood flow partially increases exercise capacity.
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2. Introduction
At the Max-Planck-Institute, Department of Experimental Cardiology, we are
investigating possible ways to protect tissues like myocardium and skeletal
muscle, which are exposed to ischemia caused by occlusion of a major artery.
Protection of ischemic tissues can be achieved by two different mechanisms.
The first mechanism concentrates on the short-term protection of ischemic
tissues and includes the phenomenon of ischemic preconditioning.  It is well
known that a series of brief periods of ischemia induces an intracellular signaling
cascade involving protein kinase C and mitogen activated protein kinases.  This
signaling cascade causes transcriptional events, which finally increase the
tolerance of the tissue towards a longer period of ischemia.  The application of
different growth factors including FGF–1 and FGF–2 before a longer period of
ischemia mimics the phenomenon of ischemic preconditioning.
The second mechanism involves the growth of blood vessels that are capable of
conducting blood flow to the ischemic tissues.  Arteriogenesis, the growth of
preexisting collateral arterioles by mitotic cell division and after DNA replication
of endothelial and smooth muscle cells, is thought to be the only functionally
relevant process to increase blood flow to the ischemic tissues.  Arteriogenesis is
induced by occlusion of a major artery and serves as a rescue mechanism for the
distal tissues.
Tissue ischemia is tolerated only for a short period of time whereas
arteriogenesis requires at least one day to become functionally relevant.
Therefore, we investigated whether the stimulation of short-term tissue
protection could bridge the gap between the time requirements from the onset of
ischemia to the increase in collateral dependent blood flow.
Furthermore, we studied possible ways to increase the collateral blood flow to the
ischemic tissues.  Therefore, it was necessary to explore the mechanisms of vessel
growth in general and of preexistent collateral arterioles in particular.
The ideal approach would be to increase the short-term protection and at the
same time enforce and accelerate the long-term protection via stimulation of
vessel growth to the ischemic tissues possibly by the same growth factor or by
combined treatments.  Increasing the tolerance towards ischemia and restoring
blood flow as fast as possible could reduce or even prevent tissue necrosis and
potentially safe hearts, brains, limbs, and therefore, many lives in the Western
society.
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The studies presented here relate to these two important topics and mainly
utilize transgenic mouse models.  These studies contribute to other investigations
considering the action of various growth factors and chemokines by providing
information about some important and unknown features.
Using our own system of cardiac-specific overexpression of FGF–1, we
investigated the cardioprotective effect of FGF–1 on isolated ventricular cardiac
myocytes subjected to different periods of simulated ischemia and subsequent
reoxygenation.
We studied the effects of cardiac-specific overexpression of fibroblast growth
factor 1 (FGF–1) on the development of coronary arteries and arterioles.
Therefore, we determined the coronary flow using ex vivo perfusion of the
coronary system under maximal vasodilation at four different pressures.
To explore the effects of general overexpression of FGF–2 on the development of
collateral arteries, we occluded the femoral arteries of FGF–2 transgenic and
nontransgenic animals.  In addition, a sub-population of each group was
submitted to regular endurance training to determine if there is any treatment
interaction between FGF–2 application and endurance training.
We accessed the effects of cardiac-specific overexpression of monocyte
chemoattractant protein 1 (MCP–1) on the development of congestive heart
failure (CHF) due to myocarditis.  Exercise intolerance as a common symptom of
congestive heart failure was determined by graded exercise tests over the period
of four months.  We explored whether the exercise capacity could serve as an
indicator for the decreased cardiac function in this animal model.
Furthermore, we investigated if exercise capacity serves as a physiological
marker of the functional capacity of hindlimbs with femoral artery occlusion.  For
this purpose we utilized three strains of mice with different dynamics in the
recovery of collateral dependent blood flow and determined the recovery of
exercise capacity after femoral artery occlusion.  Because arteriogenesis displays
different dynamics in these mouse strains we anticipated changes in the
functional capacity of the hindlimbs and thus, in exercise capacity.
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3. Review of Literature
3.1. FGFs in the Cardiovascular System
3.1.1. Biochemistry of FGF–1 and FGF–2
As early as 1939, tissue extracts of brain were shown to be a rich source of factors
that promoted fibroblast proliferation in vitro (for review see 1).  In the following
years, acid extracts of bovine pituitary were found to contain a potent polypeptide
mitogen for the murine cell line 3T3 and for chondrocytes.  The protein was
distinct biochemically from other known hormones or growth factors and
extraction conditions seemed to be important for the maintenance of the
biological activity.
In the 1970s, a basic polypeptide mitogen for 3T3 cells and mesoderm- and
neuroectoderm-derived cells was isolated from bovine pituitary and brain.  This
polypeptide was named fibroblast growth factor.  However, due to technical
difficulties its structure could not be analyzed.  Later, these difficulties were
overcome and it turned out that acidic and basic fibroblast growth factors are
related polypeptides and serve to establish the basis for a larger family of
polypeptide growth factors.  Both FGFs were also shown to be potent mitogens
for endothelial cells.  Because more growth factors belonging to the FGF–family
were discovered the nomenclature FGF–1, FGF–2, etc. has been chosen.  Acidic
and basic fibroblast growth factors were assigned the names FGF–1 and FGF–2,
respectively.
Before the structures of FGF–1 and FGF–2 were identified and the present
nomenclature was chosen other names have been ascribed to these FGFs.
Among them are eye-derived growth factor 1 and –2, endothelial cell growth
factor, heparin–binding growth factor α and –β, anionic and basic brain–derived
growth factor, hypothalamus-derived growth factor, retinal–derived growth
factor, astoglial growth factor 1 and –2, cartilage–derived growth factor,
myogenic growth factor, pituitary growth factor, bone–derived growth factor,
anionic endothelial growth factor, prostatic growth factor, and prostatropin.  The
variety of names describing their source or target cells demonstrate the potential
biological significance of FGF–1 and FGF–2.
In 1986, the primary structure of human FGF–1 derived from the cDNA clone
was identified 2.  This study demonstrated that there is a single copy of the
3. Review of Literature - 5 -
FGF–1 gene and that it is located at chromosome 5 at bands 5q31.3 to 5q33.2.
The gene encodes for a 4.8 kb mRNA.  It was shown that the open reading frame
of FGF–1 is flanked by translation stop codons and does not contain a signal
peptide or a hydrophobic domain for the secretion of FGF–1.  Later, the same was
shown to be true for FGF–2.  Sequence analysis of bovine and human FGF–1
revealed an approximate 92% sequence identity, conservation of the positions of
two of three cysteine residues, and the presence of a potential N–linked
glycosylation site.  Structural analysis of FGF–1 and FGF–2 demonstrated a 55%
homology between the two polypeptides 3.  Even though the FGF–2 gene is
located at chromosome 4, the structural similarity together with similar organ
sources and biological activities suggest FGF–1 and FGF–2 may have originated
from a common ancestral gene.
Both genes are similar in their overall organization.  They contain three exons
separated by two relatively large introns.  The major difference that appears
after analysis of the cDNAs is the precise location of the amino terminus of the
two proteins.  The termination codons flanking the open reading frame of the
FGF–1 gene were not found in the FGF–2 gene.
FGF–2 was first identified as a 146 amino acid protein isolated from bovine
pituitary 4.  The isolated form possessed a strong potency to stimulate the
proliferation of bovine aortic endothelial cells.  This effect was markedly
inhibited by acidic purification procedures.  Therefore, it was commonly referred
to as “basic” FGF.
Cloning of FGF–2 cDNA lead to a predicted length of 155 amino acids.  However,
only the 146 amino acid protein and higher molecular weight forms (196, 201,
210 amino acids) were actually isolated from tissues.  The shorter form is derived
from the 155 amino acid protein by proteolytic degradation 5.  Longer forms are
generated by initiation of translation at different CUG–codons located 5’ to the
AUG–codon, which is used for translation of the 155 amino acid protein 6.
The three forms initiated at CUG-codons have molecular masses of 22, 22.5, and
24 kDa and are predominantly located in the nucleus.  The AUG-initiated form
with a molecular mass of 18 kDa is primarily localized in the cytoplasm.
However, the occurrence of the different forms may depend upon the specific cells
examined and the expression levels of FGF–2.
The 18 kDa form of FGF–2 contains 12 anti–parallel β–sheets organized into a
trigonal pyramidal structure.  Amino acid residues 13–30 and 106–129 are
believed to be involved in receptor binding 7.  Serine 64 and threonine 112 are
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potential phosphorylation sites, which can be phosphorylated by protein kinase A
and protein kinase C, respectively 8.  Even though FGF–2 contains four cysteine
residues, there are no intramolecular disulfide bonds.
The high molecular weight forms of FGF–2 have an amino terminal extension as
a unique feature.  The 24 kDa form contains nine glycin–arginine residues, of
which seven are methylated 9,10.  However, neither the exact number nor the
functional significance of the methylated arginines of the high molecular weight
forms is known, but they might be involved in nuclear transport or retention.
Figure 1.  Schematic structure of FGFR1.  A.  The overall structural organization
is similar for the four FGF receptors.  The extracellular domain (EC) contains two
or three immunoglobulin(Ig)-like domains, followed by the transmembrane (TM)
stretch, the juxtamembrane (JM) domain, the kinase domain (KD) interrupted by
a short kinase insert, and a C–terminal tail (CT).  The positions of the tyrosine
residues in the intracellular domain are indicated.  The acidic box indicated in
the intracellular domain is a specific feature of FGF–receptors.  B.  The positions
of identified phosphorylatable tyrosine residues are indicated in the ligand-bound,
dimerized FGFR1.  Tyrosine phosphorylation sites in other FGF receptors remain
to be determined.  However, FGFR2, FGFR3, and FGFR4 all contain tyrosine
residues corresponding to tyrosines 653, 654, 730, and 766 in FGFR1 (reprinted
from 11).
FGF–1 and FGF–2 interact with specific cell surface receptors, of which four
major families have been identified; FGFR1, FGFR2, FGFR3, and FGFR4.  These
receptors share common features like a conserved cytoplasmic tyrosine kinase
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domain, a transmembrane domain, and an extracellular ligand-binding domain
(Figure 1).  The composition of the ligand-binding domain differs between the
splice–variants.  They contain either two or three immunoglobulin(Ig)–like loops.
The existences of additional splice variants with sequence modifications in the
intracellular portions of the protein have been demonstrated (for review see 11).
FGF binding induces autophosphorylation of the receptor and receptor
association with putative substrates such as phospholipase C–γ.  The long–term
mechanism of FGF–1 and FGF–2 action involves growth factor translocation to
the nucleus.  After at least 12 hours of stimulation with FGF–1, the maximal
DNA synthesis of 3T3 cells was achieved 12.  In stimulated cells, the FGFR1 was
phosphorylated and translocated perinuclearly.  At the same time FGF–1
accumulated in the nucleus.  Therefore, it was concluded that signaling through
the FGF receptor might occur at the plasma membrane and after receptor
translocation to an intracellular site.
However, receptor-independent mechanisms for FGF–1 stimulation of
proliferation have also been proposed 13.  FGFR expression levels change
markedly and during proliferation, differentiation, or malignant transformation.
FGFR expression levels during differentiation for example differ depending on
the experimental conditions and cell types used and therefore, no general
conclusion about FGFR expression levels can be derived.
3.1.2. Cardiovascular Background
Ischemic heart disease caused by stenosis or occlusions of the coronary arteries
represents the major cause of mortality in western societies.  Two distinct
physiological processes can help in maintaining the viability of ischemic
myocardium: the development of an effective vascular collateral system, and the
effect of myocardial preconditioning, the endogenous protection of cardiac
myocytes against ischemia.
During the last decade, extensive research has been dedicated to the basic
mechanisms responsible for the formation and enlargement of blood vessels in
ischemic tissues.  It was mainly focused on the role of growth factors as
modulators of vascular growth due to their capacity for directing the proliferation
and differentiation of cells composing the vascular system.  FGF–1, FGF–2,
vascular endothelial growth factor (VEGF), insulin-like growth factor 1 (IGF–1),
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platelet derived growth factor (PDGF), and angiopoietins have received special
attention.
FGF–1 and FGF–2 are potent angiogenic factors inducing capillary formation.
Their mitogenic capacity for endothelial cells is even stronger than that of the
endothelial specific mitogen VEGF (for review see 14).  Additionally, both FGF–2
and VEGF have been demonstrated to act synergistically in vitro 15 and in
vivo 16.  Unlike VEGF, FGF–1 and FGF–2 also induce vascular smooth muscle
cell (SMC) proliferation and migration in cell cultures 17, constituting exceptional
candidates for the regulation of vascular development and growth after an
episode of ischemia.
FGFs are members of the heparin binding family of growth factors.  Due to their
high affinity to heparin, FGF–1 and FGF–2 commonly accumulate in the
extracellular matrix.  They bind to heparin sulfate proteoglycans, which aid in
the protection against protein degradation.  Indeed, with a half lifetime of about
15 minutes, unbound FGF–1 is very rapidly degraded by proteases 18.
FGF–1 and FGF–2 proteins lack a signal peptide sequence for secretion from
cells 19.  Their secretion in vivo is still not entirely clarified.  In the normal heart,
FGF mRNA has been shown to be expressed by cardiac myocytes, and the protein
located to both myocytes and extracellular matrix 20,21.  In contrast, FGF
receptors are normally not expressed by cardiac myocytes and endothelial
cells 22.  However, FGF receptor and ligand have been demonstrated to be
upregulated during ischemia in several animal models 23,24.  These observations
have led to the hypothesis that a tight regulation of FGF receptors might be a
basic mechanism for the control of vascular growth during ischemia.  This type of
regulatory mechanism has been shown to be important for tumor angiogenesis 25.
FGF protein bound to heparin sulfate proteoglycans and stored in the
extracellular matrix might serve as a growth factor reservoir, ready to bind its
receptor on endothelial cells and SMCs under ischemia-induced upregulation.
3.1.3. FGFs in Therapeutic Angiogenesis
There is accumulating evidence from studies, in which the induction of
angiogenesis for therapeutic purposes is investigated, demonstrating the
importance of FGF–1 and FGF–2 for the vascular response against ischemia.  In
these in vivo experiments, native, recombinant, or vectors coding for the FGF
protein are locally or systemically infused in animals subjected experimentally to
3. Review of Literature - 9 -
ischemia.  Two main experimental designs have been used.  The model of chronic
myocardial ischemia, in which one branch of the coronary arterial tree is
gradually stenosed by ameroid constrictors, was mainly developed in dogs and
pigs.  The model of acute hindlimb ischemia, in which the femoral artery is
chirurgically excised or occluded, was designed for rabbits.
The first study on the therapeutic potential of FGF in the ischemic heart was
conducted by Banai and collaborators utilizing the dog model 26.  Locally
delivered FGF–1 via a soaked sponge induced SMC hyperplasia in arterioles and
small arteries in the area of the subendocardial infarction.  No effect on capillary
growth was detected.
In a more recent study, López et al. used the porcine model of chronic left
circumflex artery occlusion by Ameroid constrictors to test the effect of FGF
application 27.  In this study FGF–1 together with heparin were administered
perivascularly via sustained release from a polymer matrix.  The matrix was
implanted in the course of the occluded left circumflex coronary artery.  Treated
animals showed significantly improved myocardial blood flow in the compromised
territory under resting coditions and during pacing as well as enhanced global
and regional left ventricular function.  However, the study did not provide
conclusive evidence on how FGF–1 released at the epicardium can induce
collateral vessel growth in the endocardium where it usually occures in the pig.
Other experiments with the model of chronic myocardial ischemia have also
demonstrated improved myocardial function and collateral flow, as well as new
vessel formation after local or systemic administration of FGF–2 28-31.
Similar results have been obtained with the rabbit model of hindlimb ischemia.
Administration of FGF–1 intramuscularly 32, or of cDNA coding for a secreted
form of FGF–1 systemically 33 resulted in improved perfusion, increased number
of capillaries, and augmented angiographically visible collateral arteries (for
other studies of therapeutic FGF application see chapter 3.3.8).
These studies provide evidence that FGF–1 and FGF–2 play important roles in
the response of hypoxic tissues to ischemia, increasing blood flow, and improving
muscular function.  However, the mechanisms implicated in these effects of
FGF–1 and FGF–2 are still unknown.  Several distinct physiological processes
may increase blood flow, namely the angiogenic response of the capillary system,
de-novo formation of arterioles, and the growth of collateral arteries.
Improvement in ventricular function might be the consequence of increased blood
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flow, but it could also result from a hypothetical cardioprotective potential of
FGF–1 and FGF–2.
3.1.4. FGFs in Vascular Response Against Ischemia
Angiogenesis is defined the growth of capillary tubes from pre-existing capillary
vessels or small venuoles 34.  Single endothelial cells proliferate, disrupt the
continuity of the vessel wall, invade the surrounding tissue, and form new
tubular structures, which expand the pre-existing capillary bed.
FGF–1 and FGF–2 induce capillary tube formation in vitro and are able to
increase the capillary density of ischemic organs in vivo.  However, it is currently
believed that capillaries are not able to conduct enough blood flow to ischemic
tissues of larger sizes, when the stenosis affects the perfusion of a large tissue
mass.
Resistance vessels are the major determinants of blood flow, and therefore they
are good candidates for increasing the blood flow to an ischemic tissue.  Very
little is known about the growth of arteries in adult organs.  De novo formation of
arteries takes place by elongation of the distal segment of terminal arterioles 35.
The capillary to which an arteriole is connected must recruit new SMCs from
surrounding pericytes or from SMCs in the distal end of the terminal arteriole,
and differentiate into a histologically mature artery 35.  This process requires
pericyte and SMC proliferation, differentiation, and matrix deposition,
resembling the embryonic or neonatal process of arterial differentiation.
The increased number of angiographically detectable vessels in the rabbit model
of hindlimb ischemia obtained after treatment with FGF–1 may represent this
type of growth 33.  In this experimental model, the whole femoral artery is
excised, so that the only source of blood to the ischemic muscles are capillaries as
well as small arteries that can grow into the ischemic tissue from nearby arteries
not affected by exision of the femoral artery.
Collateral arteries are vascular segments, which connect two feeding arteries.
The anatomical and hemodynamical characteristics of collateral arteries make
them a unique vascular resource against ischemia.  Upon stenosis of a major
artery, the collateral arteries are the only vessels able to bridge the occluded
segment, providing an effective blood supply to the ischemic tissue.  Likewise,
collateral arteries are the only vascular structures that experience a change in
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shear stress, caused by the pressure difference after an arterial occlusion.  This
increase in shear stress has a known potential effect as a vascular growth
promoter.  Moreover, after occlusion of an arterial segment, collateral arteries
begin a process of growth, called arteriogenesis that culminates in a 20 fold
increase in their final diameter, improving their flow capacity by the factor of 10,
and leading to a final compensation up to 30% of the normal maximum flow 24,36-
38.  Currently, it is thought that only the growth of collateral arteries by
arteriogenesis is able to provide enough of blood flow to the ischemic area.
With this knowledge we planned a study with mice generally overexpressing
FGF–2.  We recently established a mouse model of collateral artery development
after occlusion of the femoral artery.  We hypothesized that general
overexpression of FGF–2 would facilitate arteriogenesis.
3.1.5. FGFs in Arteriogenesis
The process of arteriogenesis consists of complete reorganization of the collateral
vessel wall, including the destruction of the old lamina media, and formation of a
new one.  The first morphological evidence of collateral growth is the activation of
endothelial cells, probably induced by shear stress.  They express cell adhesion
molecules for the attachment and migration of monocytes 39.  Once they had
migrated into the arterial wall, the activated macrophages express cytokines and
growth factors, including FGF–2 40.  These substances are most probably the
responsible signals that trigger the whole process of arteriogenesis.  Moreover,
gene expression experiments performed in our laboratory with the rabbit model
of femoral artery occlusion have shown a significant up-regulation of the FGFR1
mRNA during the first phase of collateral growth 41.  The FGFR1 is the
predominant form of the four known FGFRs expressed by proliferating SMCs 42,
suggesting that FGFR1 mediates signal transduction in proliferating SMCs, and
pointing to a crucial role of FGFs in the initial phase of arteriogenesis.
During this initial phase of growth, the internal elastic lamina of collateral
arteries is degraded, and SMCs dedifferentiate, proliferate and migrate to the
subendothelial space, forming a thick neointima, which is required to build a new
vessel 43,44.  These SMCs show an undifferentiated or synthetic phenotype with
abundant organelles, loss of basement membrane, reduced amount of α–smooth
muscle actin, vinculin, caldesmon, and calponin.  The intermediate filaments of
these cells change from desmin to vimentin during the period of migration and
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growth.  The extracellular matrix of growing collateral arteries shows a deep
rearrangement, with increased collagen IV and fibronectin secretion.  All these
characteristics indicate an extensive vascular remodeling process, probably
regulated by FGFs that resembles the embryonic development and
differentiation of arteries.
The embryonic development of arteries is a complex developmental process, in
which multiple molecular signals are implicated.  Numerous homebox genes and
transcription factors have been identified during the last years, but their
particular functions still remain unknown.  The system Tie–2/angiopoietin–1 has
been shown to participate in the regulation of the process 45, whereas PDGF
probably controls the secretion of extracellular matrix and the cellular
differentiation (for review see 46).  FGF is also implicated in the embryonic
development of arteries 47, and it is probably necessary for the cellular
proliferation and differentiation of SMCs.
Recently, a strain of transgenic mice that specifically overexpress FGF–1 in the
heart was developed in our laboratory 48.  The gross anatomy, histological
structure and ultrastructure of the hearts of these transgenic mice are normal.
However, a significant 1.5 fold increase in the density of small arteries was
noted, whereas the capillary density was unchanged.  Moreover, the number of
branches of the main coronary arteries was also significantly increased 1.5 fold.
The arrangement and anatomical disposition of the coronary arterial tree was
normal.  These results suggest that FGF–1 is a master regulator of the
development and growth of the arterial system.  The cardiac–specific
overexpression offers an appropriate animal model for the study of potential
genes involved in the development and growth of arteries in the heart during
embryogenesis and during ischemic heart disease.
The increase in the density of small arteries and in branching of the main
coronary arteries could have potential effects on myocardial flow.  Therefore, we
determined the coronary flow using ex vivo retrograde perfusion of the heart
under maximal vasodilation at four different pressures.
3.1.6. FGFs in Myocardial Ischemic Preconditioning
Ischemic preconditioning is defined as the cardioprotective effect against
ischemia obtained after repetitive short-term coronary occlusions 49.  After one or
more short cycles of ischemia, infarct development is delayed, but not prevented.
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Thus, preconditioning can limit infarct size during a temporary occlusion, but not
during a permanent occlusion.
During the last years, enormous efforts have been made to identify the factors
responsible for cardioprotection.  The aim of many of these studies was to
discover trigger factors, which could be released at the onset of ischemic
preconditioning, looking for new and efficient therapies against myocardial
infarction.  Adenosine, acetylcholine, catecholamines, angiotensin, bradykinin,
endothelin, and opioids are some of these triggers (for review see 50).  The
receptors of some of these factors are coupled to G–proteins.  It has been
proposed that their activation may converge in a common pathway, resulting in
protein kinase C (PKC) activation, which would be responsible for
cardioprotection 51.  Indeed, ischemic preconditioning can be selectively blocked
by PKC inhibitors 52,53.
Other studies have suggested that kinases other than PKC are implicated in the
mechanism of ischemic preconditioning 54,55.  Previous studies in our laboratory
demonstrated up–regulation of tyrosine receptor kinase–ligands following brief
cycles of coronary occlusion 56.  FGF–1 was one of these ligands.  In neural tissue
and skeletal muscle models, FGF–1 demonstrated trophic and protective
effects 57,58.  With this knowledge, we conducted a study on the effects of FGF–1
and FGF–2 administration before an episode of ischemia.
FGF–1 or FGF–2 was directly infused into the myocardium of pigs just before
coronary occlusion 59.  Both FGF–1 and FGF–2 infusion showed a protective
effect, which significantly reduced infarct size.  In terms of ischemic tolerance,
FGF infusion approximately doubled the time required for complete infarction.
The cardioprotection obtained after FGF infusion is probably not a general effect
of activation of tyrosine kinases, because other tyrosine kinase receptor ligands,
like VEGF, do not achieve protection 59.  On the other hand, suramin, a growth
factor antagonist, prevented FGF-induced cardioprotection, indicating that the
preconditioning effect of FGF is receptor mediated.  Moreover, when the tyrosine
kinase inhibitor genistein was infused prior to FGF, cardioprotection vanished,
indicating that receptor activation is required for the preconditioning effect of
FGF.
One possible explanation of this preconditioning effect relies on the already
known vasodilatory capacity of FGF–1 60, that might lead to improved perfusion.
However, infusion of a truncated form of FGF–1, non-mitogenic but
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hemodynamically active 60, did not result in cardioprotection, indicating that the
preconditioning effect is due to the mitogenic activity of FGFs.
In this set of experiments, FGF–1 showed a significantly stronger
preconditioning effect than FGF–2, in terms of protein concentration required to
obtain a functional response.  This result is surprising because both FGFs have
been demonstrated to bind equally to FGFR-1 and FGFR-2 in vitro 61.  However,
some studies have stressed the fact that FGF–1 has a greater importance than
FGF–2, in terms of gene expression in normal hearts 62,63.
As already mentioned, we have recently developed a transgenic strain of mice
specifically overexpressing FGF–1 in cardiac myocytes 48.  Believing that this
may be an appropriate model to study the cardioprotective effect of FGF–1, we
have performed experiments in which the left coronary artery was chirurgically
occluded.  The infarct and risk areas were quantified in tissue slices 15, 30, 45,
60, and 75 minutes after coronary artery occlusion 64.
The hearts of transgenic mice showed a significantly delayed infarct
development.  After 75-90 minutes of occlusion, however, the infarcts had
reached the same size in both transgenic and control mice.  Most likely, this
excludes the possibility that the increased arterial density of transgenic mice,
already discussed in this chapter, could cause an improved blood flow that would
have markedly reduced the final infarct size.
These results demonstrate that overexpression of FGF–1 is cardioprotective in
mice, strengthening the hypothesis of an important role for FGF–1 in ischemic
myocardial preconditioning.  However, to undoubtedly prove that transgenic
cardiac myocytes are protected against ischemia without any influence of the
vasculature, we had to conduct a new set of experiments.  The best solution for
this purpose seemed to be the isolation of ventricular cardiac myocytes and
submitting them to simulated ischemia.  The results of this study would then
prove if overexpression of FGF–1 in cardiac myocytes protects them against
ischemia without influence of the vasculature.
The next question arising would concern the pathway by which FGF–1 exerts its
cardioprotective function?
FGF ligand binding induces receptor dimerization, autophosphorylation, and
initiation of a downstream signaling cascade leading to the activation of mitogen-
activated protein kinases (MAP kinases).  Interestingly, MAP kinases have been
shown to be upregulated by transient ischemia in rats 65.  MAP kinases are
mediators of signal transduction to the nucleus, and are involved in the response
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to cellular stress such as hypoxia, activating the transcription of genes probably
implicated in the cellular responses of the myocardium against ischemia.
Further studies with our FGF–1 transgenic mouse model are needed, in order to
explore the functions and pathways of FGF–1 leading to myocardial ischemic
preconditioning, as well as in coronary vascular growth during embryonic
development, neonatal life, and episodes of ischemia.
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3.2. MCP–1 in the Cardiovascular System
3.2.1. Biochemistry of MCP–1
The study of the influence of cardiac-specific overexpression of MCP–1 on
exercise tolerance over a period of four month is a relatively small part of this
thesis.  Therefore, only a short outline about the role of MCP–1 in the
cardiovascular system will be provided.
There is accumulating evidence that MCP–1 plays important roles in
pathophysiological conditions like decompensated heart failure, myocarditis,
atherosclerosis, and inflammation.  MCP–1 is a potent chemokine attracting
monocytes to the location of its secretion.  Most chemokines have a conserved set
of four cysteine residues.  Chemokines with the amino terminal pair of cysteine
residues adjacent to each other are called C–C chemokines.  In the case of an
amino acid residue between the two cysteines they are called C–X–C chemokines.
MCP–1 is considered the most studied member of the former class, whereas
interleukin 8 (IL–8) is the best studied member of the latter.
Shortly after the discovery of the neutrophil-specific chemoattractant now called
IL–8, different independent groups purified MCP–1 on the basis of its ability to
attract monocytes in vitro.  Surprisingly, the amino acid sequence of MCP–1
indicated that the gene encoding its murine homologue had already been cloned.
It was discovered in mouse fibroblasts as a platelet-derived growth factor-
inducible gene, called JE 66.  This became a recurring theme during the following
years as more chemokines were isolated and sequenced.  Many cDNAs encoding
chemokines had already been isolated by differentially screening activated cells.
This was probably due to the fact that the genes of many chemokines are
extremely inducible, with expression levels often increasing 30- to 50–fold after
stimulation.
The genes encoding for C–C chemokines cluster at chromosome 17 (q11.2–12).
The amino-terminal region of MCP–1 is characterized by a short β–sheet
(Figure 2), designated β0.  It is otherwise disorganized and floppy, nevertheless
essential for the biological activity of MCP–1 and possibly for dimerization 67.
The following β1–sheet including serine 27, tyrosine 28, and arginine 30 is also
important for the activity of MCP–1.  Thereafter, a C–terminal α–helix follows,
which seems to interact with glycosaminoglycans.  This interaction might
enhance dimerization and high-affinity receptor binding.
3. Review of Literature - 17 -
Figure 2.  Structure-function relationships for MCP–1.  Indicated immediately
beneath the amino acid sequence of human MCP–1 are secondary structural
features of the protein, including the four β-sheets (β0–β3) and the C-terminal
α–helix.  Shown below are several experimentally generated MCP–1 variants,
including deletion mutants and mutants in which individual amino acids were
substituted.  The first line for example (2-76) indicates a variant in which the
N–terminal amino acid (number 1) was removed, leaving the amino acids 2
through 76.  D3A describes a substitution of amino acid 3.  Aspartate (D in the
single-letter amino acid code) was changed to alanine.  The 7ND variant lacks the
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amino acids 2–8.  Next to the name of each variant is a schematic of its structure
and its relative biological activity (reprinted from 68)
However, the physiological role of MCP–1 dimers remains to be clarified.  It has
been shown that MCP–1 is under physiological concentrations a monomer and
dimerization might happen at concentrations that are irrelevant 69.  However,
this does not rule out the possibility that two independent monomers might bind
simultaneously to the receptor to generate a signal.  It has also been shown that
MCP–1 as a dimer interacts with other chemokines even at physiological
concentrations 70.
MCP–1 mainly interacts with the chemokine receptor 2 (CCR2), a specific seven-
transmembrane-domain G protein coupled receptor on the surface of its target
cells.
3.2.2. MCP–1 and Atherosclerosis
The attraction of leukocytes to a specific area of the vasculature and the
migration through the underlying tissue are central key-mechanisms in the
generation of an inflammatory response, e.g. in wound healing, infections, etc..
However, many diseases with an inflammatory component are the result of this
beneficial recruitment process getting out of control.  It is generally considered
that atherosclerosis is among the group of chronic diseases, in which recruitment
of monocytes and to a lesser extent T–cells is the root of the pathology.  The
recruitment of monocytes and T–cells requires the expression of various classes
of adhesion molecules like selectins, intercellular adhesion molecule 1 (ICAM–1),
and vascular adhesion molecule 1 (VCAM–1) as well as the presence of counter
receptor molecules on leukocytes and endothelial cells (for review see 71).
Furthermore, a chemotactic gradient to guide monocytes and T–cells to the
source of the inflammatory signal is necessary.  In atherosclerosis, the
inflammatory signal originates in the vessel wall.
Oxidized low density lipoprotein (LDL) located in the sub-endothelial space plays
a role in increasing the adherence of monocytes and their migration into the
vessel wall.  Oxidized LDL upregulates adhesion molecules on endothelial cells 72
and the expression of MCP–1 in endothelial and vascular smooth muscle cells 73.
During oxidation of LDL a large amount of the phosphatidylcholine (PC) is
converted to lysoPC through phospholipase A2 activity.  LysoPC has also been
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shown to induce the expression of adhesion molecules and MCP–1 on endothelial
cells 74.  A non-oxidized, enzymatically degraded form of LDL was found in
atherosclerotic plaques.  It was demonstrated to cause monocyte adhesion and
migration to the sub-endothelium and to induce MCP–1 expression and release
from macrophages 75.
Arterial bifurcations, branches and curvatures, which typically characterize
lesion prone areas, cause alterations in blood flow patterns in these areas.
Interestingly, it has been shown that shear stress upregulates the expression of
ICAM–1 76 and MCP–1 77.
In human atherosclerotic lesions, MCP–1 has been found to be expressed mainly
by macrophages, but also by smooth muscle cells 78.  The MCP–1 protein has also
been detected on the luminal endothelium of early human atherosclerotic
lesions 79.  It was suggested that MCP–1 has an intimate involvement in the
continued infiltration of monocytes into lesions and perhaps other downstream
chronic modulatory events.
In a recent in vitro study, the effect of MCP–1 and IL–8 on endothelial cell
monolayers expressing E-selectin under flow conditions was studied 80.  It was
found that MCP–1 and IL–8 could convert monocyte rolling to a firm adhesion,
demonstrating its importance for atherosclerotic plaque development and
progression.
CCR2 mRNA is decreasing during monocyte differentiation into macrophages.
Oxidized LDL reduces CCR2 mRNA of a monocyte cell line, which is probably
due to its ability to stimulate monocyte differentiation to macrophages 81.
However, non-modified LDL possesses an opposite activity.  LDL increased CCR2
mRNA and protein levels of the monocyte cell line, resulting in increased
chemotactic response to MCP–1.  The differential regulation of CCR2 suggests
that its main function is the recruitment of monocytes from the bloodstream and
that perhaps other chemokines/receptors are more important for movement of
macrophages within lesions.  Downregulation of CCR2 receptors on monocytes
upon entering the lesion could serve to maintain the cells in a specific area of the
inflammation until other chemokine signals are transmitted.
Macrophages are present throughout all stages of atherosclerosis and are
considered to be the major inflammatory mediators during disease progression.
After entering the atherosclerotic lesion environment, macrophages function as
scavenger cells internalizing modified lipoprotein particles, becoming foam
cells 82.  Macrophages are the richest source of chemokines and growth factors in
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atherosclerotic regions, indicating that macrophages (monocytes) and, thus,
MCP–1 play a key role in atherosclerosis.  Additionally, macrophages act as
antigen-presenting cells to T–cells during the immune response, which occurs
during the disease 83.
The presence of T–cells in atherosclerotic lesions indicates that adaptive
immunological events in conjunction with inflammatory ones are implicated in
atherogenesis.  T–cells along with macrophages occur in large numbers at the
sites of plaque rupture.  Because T–cells secret inflammatory cytokines, which
are capable of inducing metalloproteinase expression by macrophages, they are
thought to be involved in the development of unstable plaques 83.  Knowing that
MCP–1 is also a chemoattractant for T–cells and, therefore, implicated in the
development of unstable plaques, things have come full circle 84.
Vascular smooth muscle cells are also a source of MCP–1 under certain
conditions.  Balloon injury provokes a transient upregulation of MCP–1 in
vascular smooth muscle cells.  Cultured rat aortic vascular smooth muscle cells
stimulated by platelet-derived growth factor showed a similar increase in MCP–1
expression 85.
Interestingly, the potent vasoconstrictor angiotensin II, playing such an
important role in many cardiovascular diseases, can directly upregulate MCP–1
expression in rat vascular smooth muscle cells 86.  Vascular smooth muscle cells
express mRNA for the MCP–1 receptor CCR2.  However, no conclusive data are
available about the role of MCP–1 as a positive or negative regulator of
proliferation.
CCR2 knockout mice crossed with ApoE knockout mice demonstrated upon
feeding with a Western type diet markedly decreased atherosclerotic lesion
formation 87.  Furthermore, MCP–1 knockout mice crossed with LDL receptor
knockout mice showed a decreased lesion size and a reduction of macrophages
within the lesion 88.  The fact that there are still macrophages in the lesions,
albeit fewer, suggests that other chemokines are also playing a role in the
disease.  On the contrary, mice overexpressing MCP–1 crossed with ApoE
knockout mice displayed accelerated atherosclerosis through an increased
macrophage number in the lesion and lipid accumulation 89.  These studies
provide direct evidence for a direct role of MCP–1 and CCR2 in monocyte
recruitment during atherosclerosis.  However, these animal models show that
interfering with a single chemokine or receptor can have profound effects on
disease progression without an effect on plasma lipids.
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3.2.3. MCP–1 and Congestive Heart Failure
Serological investigations of patients with congestive heart failure (CHF) have
demonstrated elevated circulating levels of MCP–1 90.  MCP–1 levels correlated
significantly inversely with left ventricular ejection fraction and were
particularly raised in patients with coronary artery disease, connecting
atherosclerosis with CHF.  The serum of CHF patients enhanced the generation
of superoxide anions of monocytes in vitro.  This effect could be inhibited by
neutralizing antibodies against MCP–1.
Heart failure and cardiac hypertrophy induced by pressure overload in
hypertensive rats increased the expression of MCP–1 in the heart significantly 91.
The MCP–1 protein was localized in endothelial cells and interstitial
macrophages.  The number of interstitial macrophages was increased in these
animals.  These facts suggest that MCP–1 induced macrophage infiltration plays
a role in the development of cardiac hypertrophy and failure.
In another study, CHF was induced by volume overload via an aortocaval
fistula 92.  MCP–1 expression correlated with the severity of CHF.  The protein
was localized in cardiac myocytes, endothelial cells, vascular smooth muscle cells,
macrophages, and interstitial fibroblasts, and the intensity increased with the
severity of CHF.  Interestingly, MCP–1 binding sites to the membrane fraction of
the myocardium decreased with the progression of heart failure.
Chronic nitric oxide (NO) inhibition in rats induced MCP–1 expression, vascular
inflammatory changes, medial thickening and perivascular fibrosis as a sign of
atherosclerotic changes, and cardiac fibrosis 93.  The expression of MCP–1 was
especially increased in endothelial cells and monocytes in inflammatory lesions.
One of the initial experiments of the study demonstrated the potency of MCP–1
injection into the skin of control rats recruiting monocytes to these areas.
Administration of MCP–1 antibodies resulted in an inhibition of monocyte
infiltration of rat dermis injected with MCP–1.  The experiment furthermore
revealed that there is a dose dependent effect of the antibody treatment.
Infiltration of polymorphonuclear cells into the dermis induced by IL–8 injection
was not affected by the administration of MCP–1 antibodies.  Antibody treatment
in rats with NO inhibition resulted in inhibition of the medial thickening of large
and small coronary arteries but was not able to prevent perivascular fibrosis and
cardiac fibrosis.  Furthermore, the increase in TGF–β1 (transforming growth
factor β1) and collagen I expression due to NO inhibition could not be inhibited by
application of MCP–1 antibodies.  This study demonstrates that even though
atherosclerosis and CHF are closely linked by many pathophysiological and
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anatomical features, a variety of distinct processes have to be considered.  A
major role of MCP–1 in these diseases is evident.  However, more evidence has to
be collected to precisely understand its function and influence on the different
disease processes.
3.2.4. MCP–1 and Myocarditis
In 1998, Kolattukudy et al. reported their findings about the cardiac-specific
overexpression of MCP–1 in mice 94.  Transgenic mice showed leukocyte
infiltration into the interstitium between cardiac myocytes.  The infiltrate
consisted mainly of macrophages but the presence of a significant amount of
T–cells was not observed.  At an age of 100 days these mice did not display major
fibrosis or vascular alterations.  Myocardial samples of transgenic mice analyzed
for the expression of IL–1, IL–2, IL–6, TNF–α (tumor necrosis factor α), and
TGF–β (transforming growth factor β) mRNA did not show the production of any
of these proinflammatory or morphogenic chemokines.  This indicates that there
was no local leukocyte or endothelial cell activation up to 100 days of age.
Echocardiographic analysis of approximately one year old transgenic mice
revealed a substantial cardiac hypertrophy and dilation when compared to
nontransgenic control mice.  Left ventricular mass and both systolic and diastolic
left ventricular internal diameters were increased and contractile function was
decreased.  Heart mass of transgenic mice was increased by approximately 65%.
Histological analysis of the myocardium of these mice showed hypertrophy of
myocytes, mild interstitial edema, moderate myocarditis and a limited amount of
fibrosis.  These findings closely resemble the situation in humans with
myocarditis.  Thus, targeted expression of MCP–1 in the adult heart muscle
produces a pathological condition that shares many features associated with
myocarditis/cardiomyopathy.
In another study, the contribution of monocytes/macrophages to compensatory
neovascularization was evaluated in the same transgenic mouse line with
cardiac-specific overexpression of MCP–1.  The investigators observed tunnels in
the myocardium of these mice that were free of endothelium and occasionally
contained blood-derived cells.  Their data suggest that monocytes/macrophages
drill tunnels by using the broad-spectrum mouse macrophage metalloelastase.
Tunnels were characterized by neo-endothelial markers and proliferation
markers suggesting an active angiogenic process.  However, this study does not
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show whether these tunnels eventually become capillaries connected to an
existing vessel and colonized by circulating endothelial cell progenitors.
Data available from the literature prove that MCP–1 is a potent chemokine
influencing inflammatory events, atherosclerosis, congestive heart failure, and
myocarditis.  Cardiac-specific overexpression of MCP–1 results in a pathological
condition that closely resembles the situation in humans suffering from
myocarditis.  Preliminary experiments performed in our laboratory demonstrated
the development of severe congestive heart failure in these transgenic mice.
Exercise tolerance is used as a primary marker for the severity of CHF in
humans and the base of the New York Heart Association (NYHA) classification
system.  In order to evaluate whether these mice demonstrate impaired exercise
tolerance and to evaluate the progression of heart failure we conducted
experiments to access the exercise capacity of these mice every four weeks
starting at an age of 16 weeks.
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3.3. Physical Activity - Angiogenesis and Arteriogenesis
3.3.1. Introduction
Physical activity-induced sprouting and formation of new capillaries
(angiogenesis) in the exercising muscle has been reported as early as 1934 95.  In
the 1960s, the increased number and/or size of collateral vessels in patients with
peripheral arterial obstructive disease (PAOD) due to exercise had been
postulated 96-98.  The development of functionally relevant arteries from
preexistent collateral arterioles (arteriogenesis) was hypothesized and later
confirmed 99.
The induction of angiogenesis and arteriogenesis are considered very important
therapeutic goals in the treatment of PAOD.  Ever since the initial findings of
vascular changes and adaptations to physical activity, great efforts have been
made to determine the underlying mechanisms.
Therefore, this chapter is written to:
- Summarize the physiological adaptations of the vasculature to physical
activity,
- Explore their underlying mechanisms,
- Suggest new methods for therapeutic use of physical activity in the 
treatment of PAOD.
3.3.2. Physical Activity and Angiogenesis - Background
Angiogenesis is mainly occurring in pre- and neonatal developmental stages and
usually finished at the onset of adulthood.  However, numerous studies have
demonstrated that angiogenesis is a common adaptation of the adult skeletal
muscle in response to exercise (for reviews see 100,101).
The angiogenic response of the rabbit extensor digitorum longus muscle to low-
frequency stimulation could be observed four days after the onset of
stimulation 102.  Daily endurance treadmill running increased capillary-to-fiber
ratio of the rat gastrocnemius and soleus muscles within one week of training 103.
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These studies indicate that angiogenesis is occurring during relatively short
stimulus duration.  They also demonstrate the increase in capillary-to-fiber ratio
for the entire duration of the skeletal muscle stimulation.  Nevertheless, upon
cessation of the exercise regime, the angiogenic adaptation to increased physical
activity is reversed under physiological conditions 104.  It is unknown, whether
the exercise-induced increase in capillarity is reversible or persistent under
pathophysiological conditions like PAOD.
It is generally believed that angiogenesis is mediated by certain growth factors
that act on endothelial and vascular smooth muscle cells.  Since the early 1990s
it became apparent that these growth factors are released in response to physical
activity.
3.3.3. Vascular Endothelial Growth Factor
Vascular endothelial growth factor (VEGF) is one of the growth factors that
received a lot of attention in this context.  The homodimeric glycoprotein is
known to exist in at least five isoforms.  Three different receptors that are
restricted to endothelial cells have been characterized 105-107.  In 1995, Hang et
al. 108 reported upregulation of VEGF gene expression in skeletal muscle of the
rat exposed to electrical stimulation.  This observation was confirmed by Breen
and coworkers 109, who found increased skeletal muscle VEGF mRNA in rats
after a single exercise bout.
In 1999, two independent groups observed increased VEGF mRNA levels after
single exercise bouts in human skeletal muscle 110,111.  VEGF expression is
known to be stimulated by hypoxia 112,113, which seems to be at least partially
mediated by hypoxia inducible factor 1 (HIF–1) 114.  Gustafsson et al. 1 1 1
investigated the relationship of VEGF and HIF–1 mRNA in response to exercise.
These investigators found that the exercise-induced increase in expression levels
of VEGF correlated with the increase in HIF–1α and HIF–1β mRNA.
Furthermore, these changes correlated with the increase in femoral venous
lactate concentration.  However, when blood flow was restricted by 15-20%, no
further increase in the expression levels of VEGF, HIF–1α and HIF–1β could be
observed.  Similarly, in the study performed by Richardson and colleagues 110
skeletal muscle VEGF mRNA increased in response to a single exercise session.
But no further increase in the expression of VEGF was found when inhalation of
a hypoxic gas during exercise caused an even greater reduction of intracellular
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PO2.  The results of these two independent studies suggest that the increase in
VEGF mRNA is at least partially mediated by the increase in HIF–1 due to a
single bout of exercise.  The moderate skeletal muscle hypoxia caused by a single
exercise bout seems to be sufficient to induce VEGF expression.  It appeared that
normoxic exercise achieves the postulated intracellular PO2 “threshold” for the
VEGF response.  A further decrease of the intracellular PO2 either by restriction
of blood flow or inhalation of hypoxic gas during exercise does not result in a
greater elevation of VEGF expression compared to normoxic exercise.
Interestingly, chronic hypoxia (inspired O2 fraction of 0.12 for eight weeks) was
shown to attenuate resting as well as exercise-induced VEGF mRNA levels in
rats 115.  Furthermore, it was demonstrated that mRNA of two VEGF receptors
(flt–1 and flk–1) decreased in response to chronic hypoxia under resting
conditions and after exercise.  These findings could provide an explanation for
the lack of increased capillarity due to chronic hypoxia.
In 2000, Richardson et al. 116 revealed that the VEGF response to exercise is
attenuated in trained individuals, suggesting a negative feedback.  In trained
individuals capillary-to-fiber ratio increased as well as maximal skeletal muscle
oxygen extraction and oxygen conductance.  These findings are in accordance to
the current opinion: When structural and functional requirements of the
exercising skeletal muscle are met, no further angiogenic response e.g. increased
VEGF expression is needed.
An endurance exercise regime of five days in rats was shown to cause an
attenuated VEGF response 117.  After the first exercise bout VEGF expression
was maximal.  After exercise at the second day VEGF expression was still
significantly elevated when compared to resting levels but reduced when
compared to VEGF mRNA after the first exercise bout.
Recently, Gustafsson et al. 118 reported a twofold increase in VEGF at both the
mRNA and the protein levels in heart failure patients that underwent a training
regime of eight weeks.  The importance of these findings is demonstrated by the
study of Duscha and coworkers 119 who showed that capillary density is markedly
decreased in heart failure patients.  The decrease in skeletal muscle capillarity
appears to be a contributing mechanism for the exercise intolerance observed in
this patient group.  Based on the knowledge that the VEGF response to exercise
is intact in heart failure patients the role of physical activity for the maintenance
of skeletal muscle capillary density can be appreciated.
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Nitric oxide (NO) is released during exercise, induces VEGF expression in
vitro 120, and is known to be implicated in the signaling pathway of VEGF-
induced angiogenesis 121.  Benoit et al. 1 2 2 investigated the potency of NO
application for one hour to induce VEGF expression in vivo.  They observed an
increase in VEGF mRNA upon application of NO and suggested that the release
of the vasodilator NO could be involved in exercise-induced angiogenesis.
However, the magnitude of the NO-induced VEGF expression does not achieve
the exercise-induced VEGF mRNA level.
Inhibition of the nitric oxide synthase was demonstrated to attenuate the VEGF
response to a single exercise bout in rats 123.  This is again suggesting that
exercise induced NO release plays an important role in the angiogenic adaptation
of the skeletal muscle by either inducing VEGF transcription or increasing VEGF
stability.
3.3.4 FGF–1 and FGF–2
The fibroblast growth factor (FGF) family and the mediating receptors have
extensively been studied (for reviews see 124-126).  FGF–1 and FGF–2 were shown
to induce angiogenesis in vitro and in vivo 127,128.
In contrast to VEGF expression, the response of FGF–1 and/or FGF–2 expression
to physical activity remains to be determined.  It was found that chronic
electrical stimulation of rat skeletal muscle for five days leads to elevated mRNA
levels for FGF–1, FGF–2, FGF receptor 1 (FGFR1), and FGF receptor 4
(FGFR4) 129.  After longer stimulation FGF–1 and FGFR4 mRNAs decreased to
normal levels, whereas FGFR1 mRNA returned to normal levels after ten days
but increased again after 20 days of stimulation.  FGF–2 expression remained
elevated over the whole experimental period.  When satellite cell cultures were
stimulated FGF–1 and FGF–2 expressions also increased but to a lesser extend
in comparison to intact skeletal muscle.  FGF–1 and FGF–2 proteins increased in
electrically stimulated rabbit skeletal muscle.  These changes were concomitant
with increased mitotic activity, fast to slow skeletal muscle fiber conversion and
increased capillarity 130.
A short-term exercise program of rats did not cause increased FGF–2
expression 117 when compared to resting levels.  A single bout of submaximal
exercise also didn’t lead to a response of FGF–2 expression 123.  There was no
FGF–2 response to a single exercise bout in rats under normoxic conditions or
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after a chronic hypoxia period of eight weeks 115.  However, it was shown earlier
by the same group that the same exercise stimulus leads to increased FGF–2
expression in the rat 109.  In humans, these investigators reported no measurable
FGF–2 expression after a single endurance exercise bout 110.  Similarly,
Gustafson and coworkers did not observe increased FGF–2 mRNA after a single
exercise bout in the human 111.
A short-term exercise program in rats with bilateral femoral artery occlusion led
to increased capillarity in the gastrocnemius muscle when compared to sedentary
control rats 131.  The increase in capillarity was caused by endothelial cell
proliferation.  However, FGF–2 content of the gastrocnemius muscle was not
altered by exercise, suggesting that other endothelial cell mitogens are
responsible for the observed changes.
Overload of a particular skeletal muscle by removal of the synergist has been
reported to cause increased capillary-to-fiber ratio 132.  This change was not
associated by an increase in FGF–2 expression.  No FGF–2 immunoreactivity
was observed in capillaries, whereas it was present in larger vessels and nerves.
There was no difference in maximal muscle blood flow between overloaded
muscle and muscle of unoperated control rats, suggesting that neither FGF–2 nor
increased blood flow are responsible for the increase in capillarity.
The role of FGFs in exercise induced angiogenesis remains to be clarified.
Electrical stimulation of rat skeletal muscle appears to induce expression of
FGF–1 and FGF–2 mRNAs and to increase their protein levels.  However, most
of the endurance exercise studies in both rats and humans did not lead to a
significant response of FGF expression.  It has to be mentioned that most of these
investigations concentrated on the expression levels while paying no attention to
the protein levels.
It has been questioned whether FGF–1 and FGF–2 are secreted via the
endoplasmic reticulum since they lack the conventional leader sequences.
Cellular damage and stretching as well as a contraction based mechanism have
been suggested to cause the release of FGFs from cells in vivo 133-137.  Thus, a
possible influence of physical activity on the release of intracellular FGFs can not
be excluded and further investigations are needed.
Recently, Maciag and colleagues started to resolve the puzzle of FGF–1 release.
The release of FGF–1 may proceed through a novel release/export pathway.
They found that FGF–1, but not FGF–2, is released as a latent homodimer by a
transcription- and translation-dependent mechanism in response to a variety of
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cellular stresses including heat shock 138, hypoxia 139, and serum starvation 140.
The disruption of communication between the endoplasmic reticulum and Golgi
apparatus by brefeldin A does not prevent the release of FGF–1 from 3T3
cells 138, which confirms that FGF–1 release may occur through a
nonconventional pathway.  FGF–1 is released in vitro complex sensitive to
reducing agents and denaturants.  The complex contains the p40 extravesicular
domain of the calcium-binding protein p65 synaptotagmin 1 141.  The expression
of synaptotagmin 1 is essential for the release of FGF–1 in response to stress 142.
Furthermore, it was demonstrated that FGF–1 isolated from tissues as a high
molecular weight aggregate exists as a component of a noncovalent heparin-
binding complex with p40 synaptotagmin 1 and S100A13, a member of the S100
gene family of calcium-binding proteins 143.  The precursor form of interleukin 1α
was shown to block the release of FGF–1 suggesting that their release pathways
may be mechanistically linked 144.  The anti-allergic drug amlexanox, which
binds S100A13, is able to inhibit the release of FGF–1 and p40 synaptotagmin 1
in response to temperature stress 145.  Amlexanox also causes the reversible
disassembly of actin stress fibers indicating that the actin cytoskeleton also plays
a role in the regulation of FGF–1 release.  The expression of S100A13 facilitates
the release of FGF–1 into the extracellular compartment in response to
temperature stress in vitro 146.  Interestingly, the expression of S100A13 was
demonstrated to reverse the sensitivity of FGF–1 release to inhibitors of
transcription and translation 146.  S100A13 may also induce the formation of a
noncovalent FGF–1 homodimer, which is essential for FGF–1 release 146.  The
most recent study of Maciag and colleagues showed that copper induces the
formation of a multiprotein aggregate between S100A13, FGF–1, and
p40 synaptotagmin 1 147.  When copper was bound by a copper chelator, the heat
shock-induced release of FGF–1 and S100A13 was repressed in a dose-dependent
manner.  However, the mechanism by which the multiprotein complex is finally
released to the extracellular space remains to be determined.  Maciag and
colleagues anticipate that phosphatidylserine flipping from the inner leaflet to
the outer leaflet of the plasma membrane might be involved in this mechanism
since S100A13, FGF–1, and p40 synaptotagmin 1 are phosphatidylserine-binding
proteins 146.
Since FGF receptors are not restricted to endothelial cells and biological effects of
FGFs on other cell types have been shown, skeletal muscle adaptations in
response to physical activity beyond angiogenesis remain to be determined.
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3.3.5. Other Growth Factors
The angiogenic effect of transforming growth factor–β1 (TGF–β1) is not directly
mediated (for review see 148).  However, TGF–β1 is essential in the process of
vasculogenesis 149,150.  A shear stress response element located in the TGF–β1
promoter region causes increased TGF–β1 expression of vascular endothelial cells
upon submission to increased shear stress in vitro and in vivo 151,152.  A single
exercise bout as well as hypoxia at rest increased TGF–β1 expression in rats 109.
However, exercise under hypoxic conditions did not further increase TGF–β1
mRNA.  To precisely determine the role of TGF–β1 expression in response to
exercise further studies on different species are needed.  The long-term effects of
exercise on TGF–β1 expression also with regard to shear stress-induced
regulation remain to be determined.
Platelet derived growth factor (PDGF) expression is induced through shear stress
via two shear stress response elements in its promoter region 153-155.  PDGF is
similar to TGF–β1 essential for vasculogenesis 156.  However, no studies have
been performed investigating the effect of exercise on PDGF expression even
though increased mRNA levels could be expected via greater shear stress due to
exercise.
Endothelial cell-stimulating angiogenic growth factor (ESAF) has been shown to
be implicated in angiogenesis possibly via regulation of enzymes involved in the
angiogenic process like procollagenase, prostromelysin 1, progelatinase A, and
tissue inhibitor of metalloproteinase 1 (TIMP–1) 157,158.  Brown et al. 159 reported
that chronic electrical stimulation of rat skeletal muscle leads to increased
activity of ESAF.  The same was demonstrated to occur in overloaded skeletal
muscle of the rat 132.
Even though a close relationship between angiopoietins and VEGF has been
observed and their importance in the process of blood vessel formation has been
demonstrated 160,161 no studies have been published regarding the influence of
physical activity on this new group of growth factors.
3.3.6. Physical Activity and Arteriogenesis - Background
One of the first studies that explored the role of exercise for the treatment of
PAOD was done by Foley in 1957 162.  He reported faster healing of gangrenous
feet when patients were subjected to a walking program.  The German clinician
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Schoop focused mainly on the importance of the collateral circulation 163.  He
hypothesized that the speed of blood flow, but not ischemia, causes an increase in
the collateral circulation and that exercise is the simplest, most effective method
for augmenting the collateral circulation.  He even suggested a precise interval
training program for the treatment of PAOD.  Unfortunately, these studies were
mainly based on clinical impressions and little data were presented to prove the
hypothesis and the effect of exercise on PAOD in general and on the collateral
circulation in particular.  In 1967, Skinner and Strandness 96 investigated the
effect of a walking exercise program on three different parameters in patients
with PAOD.  Systolic pressure at the ankle after exercise, maximal walking time,
and the time of the onset of claudication pain were significantly increased in all
of the five study subjects.  They concluded, without supplying further data, that a
significant increase in collateral circulation of long-term exercised patients is
improving the blood supply to the obstructed leg.  In 1969, Alpert et al. 98
observed a significant correlation between the improvement in maximal walking
time and the increase in calf blood flow during exercise after a six months
walking regime.  Based on their results, the authors concluded that functional
factors (e.g. better coordination of the working muscles) as well as anatomic
factors (increase in the number and/or size of collateral vessels) are involved in
the improved performance of patients after regular physical activity.
In 1968, Sanne and Sivertsson 97 performed one of the first true experimental
studies with regard to exercise and PAOD.  After unilateral ligation of the
femoral artery cats were trained for five weeks on a treadmill.  The collateral
resistance at maximal vasodilation was shown to be significantly reduced in
trained cats, when compared to sedentary controls.  They also reported that the
flow resistance in the distal vascular bed was not changed after occlusion and not
affected by exercise.  Even though not providing any histological evidence they
suggested that the “spontaneous” growth of the collateral vessels in the occluded
limb was very good.  Five weeks after occlusion, the collateral resistance during
maximal vasodilation decreased almost exactly threefold in the untrained
animals.  The authors hypothesized that the “normal” stimuli for collateral
development, whatever their nature would be, are very efficient.  They concluded
that physical exercise is a very potent additional stimulus, which further
enhances the development of collateral vessels.  This study, being very elegant
for its time, was pointing into a new direction.  From there on, more attention
was paid to collateral vessel development as a therapeutic mechanism for the
treatment of PAOD.
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3.3.7. Development of Collateral Arteries
The terms “collateral circulation” and “collateral resistance” were used for
decades.  Their changes due to different treatments, interventions and
physiological processes have been detected without precisely understanding the
underlying mechanisms.  In 1971, Schaper et al. 99, who was mainly focusing on
coronary collaterals at the time, provided evidence that the fall in collateral
resistance was caused by active growth of preformed arterioles.  A new paradigm
was formed: Collateral arterioles grow by mitotic cell division after DNA
replication of endothelial and smooth muscle cells.  Recently the term
“arteriogenesis” has been ascribed to the process of collateral artery growth 164.
Arteriogenesis is now considered the only relevant type of vascular growth that
potentially saves limbs, hearts, and brains.  Angiogenesis, the growth of
capillaries, can never replace a major occluded artery.  Therefore, enhancement
of arteriogenesis is becoming the main target for researchers and physicians
involved in the treatment of PAOD.  Arteriogenesis has been shown to take place
in hindlimbs with femoral artery occlusion 40,165,166.  This process is restricted to
the thigh, whereas angiogenesis is predominantly occurring in the calf muscle
and is associated with hypoxia.  The regulating mechanisms for arteriogenesis
are not yet entirely clarified.  However, the results of several studies suggest that
the arterial diameter increases when wall shear stress is elevated 167-171.  This
process continues until wall shear stress has normalized.  It has been
demonstrated that shear stress induces expression and release of FGF–2 from
vascular smooth muscle cells and endothelial cells 172,173.  Increased shear stress
was also shown to induce expression of MCP–1 174 and the upregulation of cell
adhesion molecules in the proliferating arterioles 39.  The adhesion of monocytes
and their subsequent transformation to macrophages seems to be essential for
arteriogenesis.  Macrophages release a variety of growth factors and cytokines
known to be important for arterial growth e.g. FGF–2, MCP–1, TNF-α, and
MMPs (matrix metalloproteinases).  (see also chapter 3.2.)
3.3.8. Exercise-Induced Arteriogenesis - The Rat Model
Numerous studies demonstrated the potential role of exercise in the induction of
arteriogenesis in many species.  However, both positive and negative results have
been reported.
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The rat model of PAOD and exercise as a stimulus for arteriogenesis was mainly
established by Terjung and coworkers.  In 1986, the results of their first study
about the influence of exercise on rat hindlimbs with femoral artery occlusion
were reported 175.  Their results indicate a clear beneficial effect of exercise on
maximal running duration and intensity.  Functional performance of the
gastrocnemius-plantaris-soleus muscles in trained occluded animals was similar
to unoperated control rats but reduced in sedentary occluded animals.  However,
the blood flow determination of this muscle group by microspheres did not yet
provide conclusive results about the exercise-induced arteriogenesis with
subsequent increase in skeletal muscle perfusion during exercise.
Four years later this work was continued with slightly modified techniques 176.
After an endurance exercise program of six weeks no significant difference in
total hindlimb blood flow was observed between acutely occluded, sedentary
occluded, and trained occluded animals.  Total hindlimb blood flow reached only
46-63% when compared to unoperated control rats.  However, a significant
difference could be observed when blood flow distribution was analyzed.  Acutely
occluded animals had a markedly reduced blood flow to the gastrocnemius-
plantaris-soleus muscle group when expressed relative to the proximal blood
flow.  In sedentary occluded animals, distal blood flow partially recovered and
further increased in trained occluded animals.  The authors suggested that the
increase in blood flow to the distal hindlimb in trained animals could be due to
better collateral vessel function.  However, the total hindlimb perfusion could not
be recovered by treatment with an endurance exercise program for six weeks.
In the same year, Terjung and colleagues could detect a significant increase in
total hindlimb blood flow in rats with femoral artery occlusions trained for up to
eight weeks 177.  Again a significantly greater redistribution of blood flow to the
gastrocnemius-plantaris-soleus muscles was observed in trained occluded rats
when compared to sedentary occluded rats.
In 1993, the same group reported increased blood flow to the total hindlimb, to
proximal muscles, and to distal muscles, when the femoral artery was occluded
after pretreatment with an ACE inhibitor for up to seven days 178.  The authors
hypothesized that a larger diameter of the collateral vessels due to ACE
inhibition could be responsible for the increased blood flow.  In a follow-up
study 179, it was observed that chronic administration of an ACE inhibitor
combined with physical activity for three weeks elevated total hindlimb blood
flow and exercise tolerance to a greater extent than physical activity or ACE
inhibition alone.
3. Review of Literature - 34 -
The next pharmacological intervention applied to the same model was chronic
heparin treatment 180.  It was demonstrated that heparin treatment further
enhanced blood flow to the total hindlimb, to proximal muscles, and to distal
muscles.  Heparin treatment in combination with physical activity also increased
contractile force of the gastrocnemius-plantaris-soleus muscle group as well as
exercise capacity when compared to sedentary heparin treated animals.  This
study was particularly interesting because heparin is known to interact with
angiogenic growth factors.  Through its high-affinity binding, heparin aids in the
storage and possibly in the mobilization of growth factors in and from the
extracellular matrix (for reviews see 181-183).  It has been shown to interact with
cell surface receptors and growth factors initiating the growth factor signaling.
Therefore, it is not surprising that heparin enhances the process of collateral
artery growth by possibly potentiating the effects of growth factors released due
to physical activity.
In 1996, these investigators determined the influence of FGF–2 on collateral
artery dependent blood flow 184.  FGF–2 infusion via osmotic pumps for four
weeks markedly increased blood flow to the total hindlimb, to proximal muscles,
and to distal muscles.  Muscle performance of the gastrocnemius-plantaris-soleus
muscle group was enhanced and capillary-to-fiber ratio of FGF–2 infused rats
was increased in high-oxidative fiber sections but not in a predominantly low-
oxidative section when compared to acutely ligated rats and to heparin infused
control animals.  Postmortem angiograms revealed more collateral arteries and a
better filling of the femoral artery distal to the point of occlusion.  Thus, the
authors proved FGF–2 treatment to be very efficient in induction of
arteriogenesis upon femoral artery ligation.
When the stimulating effect of FGF–2 was combined with physical activity, a
more pronounced increase in collateral artery dependent blood flow could be
observed 185.  Hindlimb blood flow measurements compared to the sedentary
carrier group revealed an increase in the following order: trained carrier group,
sedentary FGF–2 group, trained FGF–2 group.  Interestingly, blood flow to the
proximal hindlimb muscles was especially enhanced in the trained FGF–2 group
indicating a significant treatment interaction.  However, when muscle
performance was analyzed the two sedentary groups could not maintain the
tension as well as the trained carrier group.  Again, the interaction of training
and FGF–2 application led to the highest increase e.g. muscle performance.
These data indicate that muscle performance is not just determined by blood flow
to the working muscle.  Therefore, other factors must have contributed to the
enhanced muscle performance of the trained rats.  Unfortunately, the
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investigators did not determine blood flow and muscle performance in
unoperated control animals.  It would be very interesting to compare the potency
of the combined treatment with the physiological conditions.  This could reveal
whether blood flow to the occluded limb is partially or even totally restored and
thus, the true importance of the combined treatment.  Additionally, capillary-to-
fiber ratio increased only in the low-oxidative gastrocnemius section of trained
rats opposing their findings of the previous FGF–2 infusion study 184.
In 2000, the efficacy and specificity of FGF–2 application on the increase in
collateral artery blood flow were determined 186. The investigators found similar
increases in the intra arterially infused group when compared to the intra
venously infused group or the subcutaneously injected group as long as similar
amounts were administered.  There was no obvious difference in collateral artery
blood flow when FGF–2 application was short-term or prolonged and continuous
or intermittent.  Chronic FGF–2 treatment did not alter blood flow upon acute
femoral artery occlusion when compared to untreated or carrier treated control
rats.  Therefore, the authors conclude that FGF–2-induced arteriogenesis
requires vascular occlusion and can be restricted to short-term application
though different routes to be effective.
In the same year, these investigators evaluated the influence of an endurance
exercise program before acute occlusion of the femoral artery on collateral artery
blood flow 187.  Prior endurance exercise training increased blood flow to the
hindlimb in the distal as well as in the proximal segment when compared to
sedentary control rats.  Blood flow to the gastrocnemius-plantaris-soleus muscles
was significantly increased but did not nearly reach the level of trained FGF–2
infused rats that was shown earlier 185.  These results indicate that prior exercise
training is effective in increasing blood flow to the distal hindlimb muscles upon
acute occlusion of the femoral artery.  But since there is no need for an excessive
use of the preexistent collateral arterioles during exercise with intact legs the
increase in shear stress is just enough to induce a moderate growth of these
vessels.
The most recently published study by Terjung and colleagues indicates that
nitric oxide (NO) is implicated in arteriogenesis induced by FGF–2 as well as
VEGF 188.  Nitric oxide synthase (NOS) inhibition abolished the effect of both
FGF–2 and VEGF on arteriogenesis. Both growth factors alone were capable of
increasing blood flow to the total hindlimb, to proximal muscles, and to distal
muscles to a similar extent when compared to untreated control rats.  However,
NOS inhibition together with FGF–2 or VEGF treatment resulted in unchanged
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blood flow when compared to untreated control rats.  Thus, reduced NO
production, availability, and/or responsiveness that are frequent phenomenon in
patients with PAOD and CHF 189-191, could inhibit the arteriogenic response to
FGF–2 and VEGF treatments.
Summarizing the results of Terjung and colleagues, one could speculate that the
ideal treatment for rats with an arterial occlusion would begin even before the
onset of occlusion with at least six weeks of treadmill running.  After femoral
artery occlusion FGF–2 application via different routes has proven to be
extremely effective when combined with an endurance regime for at least four
weeks.  In this model, exercise appears to multiply the effect of FGF–2 via
further increase in shear stress and increased release of NO (for review see 192).
It has also been shown that FGF–2 application to vascular smooth muscle cells
in vitro upregulates the expression of VEGF 193.  A marked synergist effect on
VEGF expression could be observed when hypoxia was combined with FGF–2
application.  This study suggests that FGF–2 and skeletal muscle hypoxia during
exercise could have promoted among other factors an amplified VEGF response
in trained FGF–2 rats.
However, Terjung and colleagues did not show that a treatment exists, which
fully restores the dilatory capacity of the normal vasculature in a hindlimb with
femoral artery occlusion.  It would be very interesting to investigate the level of
blood flow recovery to the total hindlimb that can be achieved with the “optimal”
therapy.  Nevertheless, the optimum remains to be determined.  There could be
significant additive effects of a combined VEGF and FGF–2 treatment, which
could be used even during the initial training period.
3.3.9. The Dog Model of Exercise-Induced Arteriogenesis
In the late 1970s, researchers and clinicians paid much more attention to the
possible effect of exercise on the development of the collateral circulation upon
occlusion of a major coronary artery.  Arteriosclerosis had become the leading
cause of death some years ago and cardiovascular medicine was looking for ways
to increase perfusion in areas distal to the site of occlusion.  The dog model had
been shown to be useful for clinicians, surgeons, and researchers at the time for
three reasons:
- Surgical techniques used for humans could be applied with slight
modifications.
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- Dogs develop impressive coronary collaterals that could be visualized by
angiography.
- Last but not least dogs proved to be very good runners.
In 1978, Heaton et al. 194 reported that exercise enhanced blood flow only to the
endocardium of the collateral dependent zone in dogs with occlusions of the left
circumflex coronary artery and of the distal part of the left anterior descending
artery.  The enhanced endocardial blood flow could only be observed during
exercise.  The training program of six weeks was sufficient to induce a decrease
in heart rate at a given workload.  In sedentary control animals blood flow did
not change over the same period, which would indicate that no significant
arteriogenic response occurred.  However, the baseline measurements were
performed two weeks after the initial operation, which is the period were the
main arteriogenic adaptation occurs.  Thus, these results are not indicative for
the entire process of arteriogenesis.
Neill and Oxendine 195 reported that trained dogs with occlusion of the left
circumflex coronary artery had a higher retrograde flow from the distal part of
the occluded artery when compared to their sedentary controls.  However, the
retrograde flow method does not indicate the true tissue perfusion by collaterals.
The greater pressure drop across the coronary collaterals observed in sedentary
dogs is most likely due to increased scar formation in the collateral dependent
zone of the myocardium.  There was no apparent difference in the angiographic
images of trained and sedentary dogs.  Furthermore, the microsphere technique
demonstrated that there was no beneficial effect of physical activity on blood flow
to the collateral dependent zone of the myocardium.
In 1981 196, it was reported that an exercise program initiated three months after
occlusion of the left circumflex coronary artery promotes collateral dependent
blood flow.  Again, the retrograde perfusion method used in this study does not
allow conclusions about the tissue perfusion provided by collateral arteries.
Daily low intensity exercise for six weeks did not alter collateral dependent blood
flow in control dogs with normal coronary arteries.
In 1982, our group at the Max-Planck-Institute in Bad Nauheim conducted a
study to precisely determine the role of exercise in the induction of collateral
coronary growth 197.  Therefore, we used the rigidly standardized isolated heart
model of testing regional blood flows with tracer microspheres during maximal
vasodilation and under a wide range of perfusion pressures (40-140mmHg).  The
dogs performed a vigorous exercise program (up to three month) before the left
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circumflex and the right coronary arteries were slowly occluded with ameroid
constrictors (one-vessel occlusion was used in most of the aforementioned
studies).  After a recovery period of two weeks the dogs continued the exercise
program for another 12 weeks.  The workloads used in this study were the
highest reported so far.  At the end of the training period the dogs achieved a
very high level of physical fitness.  They were able to run up an inclination of
22% and a speed of eight miles per hour for one hour.  However, there was
neither a difference in coronary nor in collateral blood flow in exercised dogs
when compared with the sedentary control animals.  Collateral conductance in
trained and sedentary dogs reached only about 40% of that of the replaced
coronary artery.  Calculated total collateral resistance of trained dogs was not
different from sedentary animals.  No significant change in mortality was
observed.  This study was mainly designed to precisely determine the influence of
physical activity on coronary collateral arteries of the dog.  The isolated heart
preparation allowed the use of fixed pressures under maximal vasodilation and
the determination of the corresponding blood flow via use of radiolabled
microspheres.  The study demonstrated that a very high level of physical activity
does not produce an increase in coronary collateral blood flow in dogs and thus,
did not provide a further stimulus for arteriogenesis.  Because of the advanced
techniques used in our study the observations are at variance with other studies
that reported beneficial effects of physical activity on collateral dependent blood
flow.  Nevertheless, we can not exclude the possibility that treadmill running at a
certain workload could have produced differences in collateral blood flow when
comparing the highly trained dogs and their sedentary controls.  Note that the
beneficial effect of exercise on final infarct size that was previously reported by
us 198 was not again assessed in this study.
A study that partially confirmed this assumption was conducted in the same
year 199.  Dogs with a stenosed the left circumflex coronary artery were trained
for 12 weeks on a treadmill using sprints and endurance running.  When
compared to sedentary controls trained dogs exhibited less evidence of left
ventricular failure (higher cardiac output, lower left atrial pressure) upon total
occlusion of the left circumflex coronary artery during a single exercise session.
Trained dogs showed improved collateral dependent blood flow at rest and during
exercise while there was virtually no improvement in the sedentary control dogs.
The authors concluded that running exercise stimulates the development of
collateral vessels in dogs with a stenosed coronary artery, and that the enhanced
collateral flow has salutary effects on myocardial function.  However, with our
findings of myocardial blood flow in mind, these results could also be interpreted
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the other way around.  Physical activity induced beneficial changes of myocardial
function during exercise, leading to enhanced perfusion of the myocardium upon
total occlusion during a given level of exercise.
In 1985, Cohen and Steingart reported their findings on coronary collateral
development after occlusion of the left circumflex coronary artery in dogs
submitted to an endurance exercise program for six weeks 200.  Using
thallium–201 scintigraphy during exercise, the investigators revealed a
significant improvement in scintigraphic measurements over the first four weeks.
Microsphere measurements showed a good recovery of perfusion distal to the site
of occlusion.  Serial angiographic studies demonstrated the development of
collateral vessels and the increase in collateral circulation to the left circumflex
coronary artery.  Cardiac output during exercise increased and the left atrial
pressure decreased significantly during the study period.  However, the lack of a
real control group makes it difficult to ascribe these beneficial effects to the
exercise regime used in this study.  Nevertheless, this study demonstrated that
collateral coronary artery development is a dynamic process and that exercise
hemodynamic measurements improve with progression of arteriogenesis.
Two years later, the same model was used to investigate the effect of an exercise
program prior to occlusion of the left circumflex coronary artery on the degree of
infarction and collateral dependent blood flow 201.  They observed no significant
change in infarct size.  The effect of exercise on collateral dependent blood flow
did not reach the level of significance.  Evaluating the parameters used in this
study, no clear beneficial role of prior exercise in cardioprotection was observed.
Cohen and coworkers 202 investigated the role of exercise training in collateral
vessel development in dogs with normal coronary arteries.  Ten to 12 weeks of
endurance exercise resulted in significant adaptations of the cardiovascular
system and skeletal muscle.  However, the increase in collateral dependent blood
flow was not significant, suggesting that exercise is not an appropriate stimulus
for significant arteriogenesis in dogs with normal coronary arteries.
In 1990, it was reported that endurance training does not induce changes in
collateral development in dogs with normal coronary arteries 203.  After an
endurance exercise regime of 12 weeks collateral blood flow determined by
microspheres was not different from sedentary animals.  The author concluded
that exercise in dogs with normal coronary arteries does not alter the
development of collateral vessels.  This suggests that arteriogenesis is not an
adaptation mechanism to an exercise program of 12 weeks in dogs with normal
coronary arteries.
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Weiss et al. 204 investigated the effect of treadmill walking for over one year on
collateral dependent blood flow in dogs with unilateral occlusions of the femoral
artery and its branches.  At the end of the exercise period blood flow during
resting conditions as well as immediately after exercise was determined by
microspheres.  Interestingly, there was no difference in blood flow between the
normal control leg and the occluded leg under both conditions, suggesting that
walking exercise induced an immense increase in collateral dependent blood flow
to hindlimb muscles.  However, due to the lack of a sedentary control group no
definite conclusion can be drawn about the true role of physical activity in this
study.
In summary, dogs with occlusion of one or two coronary arteries develop large
and well visible collateral arteries.  The collateral conductance reaches only
about 40% of that of the replaced coronary artery leaving room for therapeutic
intervention.  Exercise has failed to induce arteriogenesis.  Increases in tissue
perfusion in exercised dogs have mainly been observed during exercise but not
under pressure controlled ex vivo conditions.  Cardiac output increases, heart
rate and atrial filling pressure decrease at a given workload.  Therefore, regular
physical activity could lead to either increased myocardial perfusion at a certain
workload due to the increased cardiac output and/or to a reduced myocardial
oxygen demand at this workload due to enhanced oxidative metabolism.  These
questions remain to be solved.
Furthermore, there are no studies that undoubtedly prove the acceleration of
arteriogenesis due to exercise in dogs with femoral artery occlusion.  However,
regular physical activity causes beneficial changes of hemodynamic parameters.
Applying these results to the human should not result in questioning the
importance of physical activity.  Even without paying attention to the anatomical
and physiological species differences it should be encouraging for us that trained
dogs with coronary occlusions can develop an impressive physical fitness even
though their collateral conductance has not changed when compared to sedentary
controls.
3.3.10. The Pig Model of Exercise-Induced Arteriogenesis
Bloor and coworkers made major contributions considering the development of
coronary arteries due to exercise.  In 1984, Bloor et al. 205 investigated the effects
of exercise on coronary collateral artery development in pigs with occlusion of the
3. Review of Literature - 41 -
left circumflex coronary artery.  The investigators have chosen the pig as a study
species since it has sparse innate coronary collaterals like in humans.  Two
weeks after placing an ameroid constrictor around the left circumflex coronary
artery the pigs were assigned to an endurance exercise regime for five months.
Physical activity resulted in an increase of exercise capacity, a reduction of
infarct size, and an increase in collateral blood flow to the noninfarcted
jeopardized myocardium when compared to sedentary control animals.
Therefore, with respect to the utilized exercise regime and the experimental
protocol, it appears that collateral vessels developed primarily in or near the
ischemic zone of the myocardium and served in tissue salvage especially in the
exercised pigs.
The influence of strenuous exercise on cardiac hypertrophy as well as capillary
and arteriolar density of pig myocardium was accessed in a later study 206.  A
reduction in capillary density and an increase in arteriolar density were reported.
However, densities were accessed in number per mm2 and since myocyte cross
sectional area was shown to be increased by 21% in the trained group these data
are not conclusive.  Nevertheless, the increase in arteriolar density would then be
even more impressive when expressed as arteriole-to-fiber ratio.  Blood flow was
not significantly different at rest, during exercise, and during exercise under
maximal vasodilation.  The only change in blood flow that could be detected in
trained pigs was an increase in epicardial blood flow during exercise and exercise
under maximal vasodilation.
In 1987, these investigators reported similar results considering capillary and
arteriolar densities 207.  Additional measurements revealed increased maximal
oxygen consumption, and increased stroke volume and end-diastolic volume
during exercise.  The initial reduction in left ventricular end-diastolic diameter
during progressive exercise was abolished after the strenuous training regime.
This study is again highlighting the importance of functional adaptations of the
myocardium to exercise stimuli.  Nevertheless, arteriolar growth has been
demonstrated to be induced by strenuous physical activity in pig myocardium.
Four years later, another study was carried out to determine the effect of exercise
on myocardial blood flow and function after occlusion of the left circumflex
coronary artery 208.  An increase in systolic wall thickening during exercise could
be observed after a running regime of 25 days.  The effect of the training regime
on myocardial blood flow was best visible during severe exercise.  Subepicardial,
submyocardial, and subendocardial blood flow ratios increased significantly when
compared to the initial blood flow measurements prior training.  Neither systolic
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wall thickening or blood flow measurements during exercise changed in
sedentary control animals over the study period.  The authors concluded that the
utilized exercise regime improved myocardial function and blood flow to the
collateral dependent myocardium during severe exercise.
In summary, pigs with occlusion of the left circumflex coronary artery respond to
regular physical activity with improved myocardial performance.  Blood flow to
the jeopardized myocardium is increased at a given workload suggesting that
arteriogenesis has taken place.  Nevertheless, these results are in need of
confirmation by other techniques.  The isolated heart preparation could be useful
to detect if the increase in blood flow during exercise is induced by growth of
collaterals or by enhanced myocardial performance.  However, exercise has been
demonstrated to induce the growth of arterioles in hypertrophied myocardium of
pigs.  This growth appears to be only one mechanism for blood flow maintenance.
There are no studies available investigating the effect of exercise on
arteriogenesis after femoral artery occlusion in the pig.
3.3.11. The Mouse Model of Exercise-Induced Arteriogenesis
To the best of our knowledge, there are no studies considering the effect of
exercise on arteriogenesis in mice.  In the last years it has been a major issue for
our department to develop a mouse model of PAOD.  This was especially
important since the availability of different transgenic mice give us the
possibility to explore the factors increasing and decreasing arteriogenesis.
Transgenic animals enable us to explore the underlying mechanisms of
arteriogenesis.  The small size of the animal allows the use of very expensive and
rare compounds.  After investing a lot of time and effort, we were able to develop
a mouse model of PAOD together with the techniques to detect changes in
collateral dependent blood flow via laser doppler imaging (LDI) 209 and magnetic
resonance imaging (MRI).  We adopted our histological methods to the mouse
model to visualize arteriogenesis in the tissue.  Angiography of the hindlimbs
depicts the growth pattern of the collateral vessels.  Determination of exercise
capacity provides us with information about functional relevance of the
arteriogenesis 210.  We developed a progressive, moderate intensity exercise
program for mice with femoral artery ligation to determine the influence of
physical activity on arteriogenesis in mice.
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The first study conducted in our laboratory concentrated on the effects of general
overexpression of FGF–2 in addition to endurance exercise on arteriogenesis.
The results of this study are described and discussed in chapters 5.3. and 6.3.,
respectively.
3.3.12. Exercise and Arteriogenesis in Humans
There are numerous studies that demonstrate the beneficial effect of exercise on
increases in both pain free walking distance and maximal walking distance in
patients with PAOD (for reviews see 211,212).  However, results are conflicting
considering increased blood flow due to regular physical activity in patients with
PAOD.  There are some studies that report increased blood flow 96,98,213-215, some
studies that demonstrate unaltered perfusion 216-221, and one study even reports
a decreased resting perfusion 222.
Two recently published studies could be taken as examples for the existing
diversity.  Gardner et al. 223 reported that calf blood flow was increased in elderly
patients with PAOD after taking part in a six-month treadmill exercise program.
Blood flow was slightly elevated under resting conditions and more pronounced
under reactive hyperemic conditions.  The increase in reactive hyperemic blood
flow correlated with the increase in pain free walking distance.  On the other
hand, Tan et al. 224 reported that three month of exercise training did not result
in an increase in common femoral artery blood flow.
Explanations for the opposite findings might involve methodological differences
in accessing blood flow.  There is no “gold standard” that has been established
previously and is now used in all of the studies.  Furthermore, blood flow is
determined at various time points and under different conditions.  The length
and the intensity of the exercise regime differ markedly.  There is no consensus
whether blood flow should be accessed under resting conditions, during or
immediately after exercise, or during reactive hyperemia.  These studies were
conducted over a period of almost 40 years, which might explain the use of
different methods.  Nevertheless, establishing a widely accepted standard for
measuring blood pressure in the human could solve this problem for further
studies.
It has to be mentioned that exercise proved to exert beneficial effects on
endothelial function of patients heart failure 225.  Therefore, the beneficial effect
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of exercise training on blood flow could also be ascribed to enhanced endothelial
function in some of the experimental settings.
Furthermore, exercise influences a variety of other factors that are likely to
contribute to the increase in maximal walking distance.  These factors include
skeletal muscle metabolism and morphology, blood rheology, regression of
atherosclerosis, walking economy, pain perception, and cardiac adaptations (for
review see 226).
Human studies on PAOD often lack histological evidence that exercise induced
arteriogenesis.  While the induction of angiogenesis can be detected by using
muscle biopsies only postmortem tissue preparations could provide the
histological evidence for arteriogenesis.  Angiography is another tool to determine
collateral artery growth but was unfortunately very rarely utilized by most of the
studies.
Growth factors therapies for cardiovascular diseases are presently evaluated in
clinical studies mainly focusing on coronary collateral development.  However,
many problems and unresolved issues appear as these trials proceed (for review
see 227).  A definite answer on which growth factor is effective in the induction of
arterial growth in different cardiovascular diseases can not undoubtedly be
given.
There is no study investigating the combined effect of regular physical activity
and growth factor treatment in humans.
In conclusion, there is no definite evidence for induction of arteriogenesis in
patients with PAOD.  However, exercise has been proven to be beneficial for
maximal walking distance and quality of life of these patients.  Further studies
are needed to investigate the role of exercise for arteriogenesis in humans
suffering from PAOD.
3.3.13. Summary
That exercise induces angiogenesis has been demonstrated for almost 70 years.
The reason for this phenomenon has been discovered during the last years.
Expression of various angiogenic growth factors in response to a single exercise
bout or to electrical stimulation was demonstrated in different animal models as
well as in humans.  Among these were VEGF, TGF–β, FGF–1 and FGF–2
including their receptors, and ESAF.  However, other potent growth factors like
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PDGF and angiopoietins have not been investigated.  Angiogenesis is an
important adaptive mechanism to increased physical activity.  It can be
appreciated that the more capillaries are surrounding a skeletal muscle fiber the
better is its supply with oxygen, glucose, and free fatty acids.  The removal
lactate and carbon dioxide is facilitated by this adaptation.  Thus, there is no
doubt about the structural importance of angiogenesis for enhancing the function
of exercising skeletal muscle.
However, the importance of angiogenesis is reduced in magnitudes when the
blood supply of the skeletal muscle is limited by occlusion of a major artery.  Here
arteriogenesis is the dominant factor.  Preexisting collateral arterioles grow by
mitotic cell division and after DNA replication of endothelial and smooth muscle
cells.  The developing arteries are capable of replacing a substantial amount of
blood flow and therefore provide the prerequisite for survival of the distal tissues.
Early studies in cats and in rats demonstrated the increase in blood flow through
these collateral arteries in response to endurance exercise.  The increase in shear
stress and the release of growth factors due to endurance exercise probably
mediate this response.  Early studies in dogs suggested a beneficial effect of
exercise on growth of coronary collateral arteries.  However, this could not be
confirmed by investigation of collateral dependent blood flow utilizing a rigidly
standardized isolated heart model.  Exercise leads to cardiovascular adaptations
that most likely caused these false positive results.  Nevertheless, the
improvements in cardiac function are impressive and of importance for patients
suffering from myocardial infarction.  Data obtained in pigs do not conclusively
prove the enhanced development of collateral coronary arteries due to exercise.
However, exercise was shown to induce arterial growth in normal myocardium of
pigs.  There are only a few studies in dogs and pigs investigating the role of
exercise in PAOD.
More recent studies in rats demonstrated the potential of growth factor
application in addition to exercise.  When comparing to single exercise or growth
factor treatment the combination of both is much more effective when
considering the increase in hindlimb blood flow and muscle performance.
Our latest study in a transgenic mouse model of PAOD indicates a significant
treatment interaction between FGF–2 and regular physical activity (see also
chapters 5.3. and 6.3.).  We observed a different collateral growth pattern with
formation of a dense vascular network.  Although to a lesser extent, the same
pattern was found in trained nontransgenic mice suggesting that physical
activity induced branching and growth of the preexisting collateral arterioles.
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This response appears to be more effective than just the enlargement of a few
collateral arteries exhibiting the corkscrew growth pattern.
In conclusion, there is enormous evidence about the induction of angiogenesis by
regular physical activity.  The expression of various growth factors is mediating
this process.  Enhanced arteriogenesis due to physical activity has been
demonstrated in some animal models but not in others.  Although it is evident
that patients with cardiovascular diseases benefit from endurance exercise,
enhanced arteriogenesis has not yet proven to be one of the main reasons for this
beneficial effect.  Recent studies in rats and mice have demonstrated that growth
factor application causes a significant treatment interaction with endurance
exercise.  It is of immense importance to extent these first encouraging studies to
other animal models and finally to the human patient.  This powerful approach
could potentially cure thousands of patients suffering from cardiovascular
diseases.
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4. Methods
4.1. Animals
The present studies were performed with permission of the State of Hessen,
Regierungspräsidium Darmstadt, according to section 8 of the German "Law for
the protection of animals."  The investigations conformed with the National
Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals
[DHHS Publication No. (NIH) 85–23, Revised 1985, Office of Science and Health
Reports, Bethesda, MD 20892].  All mice were housed in standard cages,
maintained on a 12 hour light and 12 hour dark cycle, and received water and
chow ad libitum.
4.1.1. FGF–1 Overexpressing Mice
For experiments of simulated ischemia 18 mice with cardiac-specific
overexpression of FGF–1 (FGF–1 transgenic) were used.
A 2.2 kb EcoRI fragment of clone pHBGF1.3A, including the coding and the 3’
untranslated sequence of human FGF–1 but lacking any signal sequence, was
ligated between the SV40 large intron and the 2.2 kb mouse MLC2v promoter.  A
CMV enhancer was positioned upstream from the MLC2v promoter, which
provided the cardiac-specific expression (plasmid CMV/MLC2v/FGF) (Figure 3).
The nontransgenic littermates (n=18) served as control mice.  The mice were
generated at the Max-Planck-Institute, Department of Experimental Cardiology.
The same strain of FGF–1 transgenic mice was used for determination of a
pressure-flow-relationship (eight FGF–1 transgenic mice and seven
nontransgenic control mice).  The mice were 12 weeks old at the onset of the
studies.  (For detailed description of the generation of FGF–1 transgenic mice
see 48.)
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Figure 3.  Schematic drawing of the construct used for generation of FGF–1
transgenic mice.  The human full-length FGF–1 cDNA was linked to the murine
MLC2v promoter for heart-specific expression and to the SV40 large intron and
polyA+ sequence for correct processing.  The CMV enhancer was linked upstream
to the MLC2v promoter for enhanced transgene expression.  BamHI restriction
sites used for Southern blotting and the length in base pairs of the fragments are
indicated (not to scale).
4.1.2. FGF–2 Overexpressing Mice
To determine the effects of FGF–2 and regular physical activity on exercise
capacity of mice with unilateral femoral artery occlusion 12 male mice with
general overexpression of FGF–2 (FGF–2 transgenic) were used.
A constitutive phosphoglycerate kinase promoter and polyadenylation sequence
were used for general overexpression of FGF–2.  A human FGF–2 cDNA was
ligated to the promoter with a short intronic sequence inserted between the
promoter and the FGF–2 cDNA in plasmid Blueskript II SK.  The founder
generation of FGF–2 transgenic mice was kindly provided by Dr. J. Douglas
Coffin of the University of Montana (for detailed description of the generation of
FGF–2 transgenic mice see 228).  Breeding of the experimental animals was
conducted at the Max-Planck-Institute, Department of Experimental Cardiology.
The nontransgenic littermates (n=12) were used as control mice.  At the onset of
the study all mice were 12 weeks old.
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4.1.3. MCP–1 Overexpressing Mice
To determine the changes in exercise capacity after the onset of chronic heart
failure due to myocarditis 10 male mice with cardiac-specific overexpression of
MCP–1 (MCP–1 transgenic) were used.
A 1.9 kb EcoRI fragment of mouse JE-MCP–1 gene cloned into pUC19 plasmid
was ligated to the Sa/I–KpnI–digested Myhca clone.  The α–cardiac myosin heavy
chain gene (Myhca) promoter was responsible for the cardiac-specific expression
(for detailed description of the generation of MCP–1 transgenic mice see 94).  The
founder generation of MCP–1 transgenic mice was kindly provided by
Dr. Pappachan E. Kolattukudy of the Ohio State University.  Breeding of the
experimental animals was conducted at the Max-Planck-Institute, Department of
Experimental Cardiology.  The nontransgenic littermates (n=5) were used as
control mice.
At the onset of the study all mice were 16 weeks old.  Every four weeks, one
MCP–1 transgenic mouse with an exercise capacity representing the average
exercise capacity of the transgenic mice was used for histological analysis of the
heart.
4.1.4. Nontransgenic Mice
For determination of the change in exercise capacity immediately after bilateral
femoral artery occlusion male Balb/C (n=12), sv129 (n=12), or C57Bl/6 (n=12)
mice were used.  The mice were obtained from Charles River Laboratories
(Sulzfeld, Germany) at an age of 11 weeks and after an habitation period of one
week immediately used for the studies.  Six mice of each strain with unilateral
femoral artery occlusion performed at the same day were used for determination
of the recovery of collateral dependent blood flow by Laser Doppler Imaging.
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4.2. Simulated Ischemia
4.2.1. Isolation of Mouse Ventricular Cardiac Myocytes
Ventricular cardiac myocytes of FGF–1 transgenic and control mice were isolated
as previously described for rats 229 with a few adoptions.
In brief, the mice were anesthetized by intra peritoneal (i.p.) injection of a
mixture of ketamine (10 %, Medistar) and xylazine (Serum-Werk Bernburg AG).
Five IU of heparin (Liquemin N 25000, Roche) were administered.
Under a binocular microscope (Leica) the thorax was opened, the heart quickly
excised and placed in ice-cold perfusion buffer (110 mM NaCl, 2.6 mM KCl,
1.2 mM KH2PO4, 1.2 mM MgSO4, 1 mM CaCl2, 10 mM HEPES, 11 mM glucose,
pH 7.4).  The ascending aorta was cannulated with a polyethylene catheter (inner
and outer diameter 0.40 and 0.80 mm, respectively) (Portex), which was
connected with a 26 gauge hypodermic-needle (Sterican) to a 1 ml single-use
syringe (Braun) filled with perfusion buffer and 5 IU heparin.  The tip of the
polyethylene catheter was placed approximately 2 mm distal to the aortic valve.
The catheter was fixed with a 5-0 surgical suture.  Care had to be taken that the
catheter, needle, and syringe were free of air bubbles.
Next, the heart was retrogradely perfused with the content of the syringe.  The
perfusion lasted approximately 1 min and was used to control the placement of
the catheter tip, to confirm the absence of any leakage, to remove blood from the
coronary system, and to look for damage of the heart and air bubbles in the
coronary system.
Thereafter, the heart was connected to a Langendorff-perfusion-apparatus
(Figure 4) and retrogradely perfused with perfusion buffer gassed with 95% O2
and 5% CO2.  Four minutes later perfusion was switched to 0.03% collagenase
(CLS 2, Worthington Biochemical Corp), 0.004% pronase (Boehringer),
0.005% trypsin (Sigma), and 0.04 mM CaCl2 for 25 min.
Then the heart was disconnected from the Langendorff-perfusion-apparatus,
minced in the collagenase solution containing 1.2% BSA (Sigma), gently shaken
at 37°C for 5 min, filtered through a nylon mesh and centrifuged at 15g for 5 min.
The pellet was then carefully resuspended in perfusion buffer containing
0.1 mM CaCl2 and centrifuged at 15g for 3 min.  This step was repeated twice
with perfusion buffer first containing 0.5 mM CaCl2 and then containing
1.0 mM CaCl2 and 4% BSA.  The cells were resuspended in medium 199 (Sigma)
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containing 5 mM creatine, 2 mM L-carnitine, 5 mM taurine, 0.1 mM insulin,
10 mM cytosine arabinoside, and 100 IU penicillin–streptomycin.
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Figure 4.  Schematic drawing of the Langendorff-perfusion-apparatus used for
isolation of ventricular cardiac myocytes from the mouse heart.  The initial
volume of perfusion buffer in the upper reservoir was 100 ml.  Total retrograde
perfusion lasted for approximately 30 min, making a recirculation of the perfusion
buffer unnecessary.
Cardiac myocytes were plated in 35 mm culture dishes (Falcon), coated with
5 µg/ml laminin (Sigma) and 10 µg/ml fibronectin (PromoCell).  No FCS was
added to the culture medium.  Ventricular cardiac myocytes were allowed to
attach to the dish for 3h before experiments of simulated ischemia were started
(Figure 5).
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Figure 5.  Isolated ventricular cardiac myocytes of an adult FGF–1 transgenic
mouse.  Representative picture of attached cardiac myocytes plated in the
appropriate density.
4.2.2. Simulated Ischemia
Ischemia of adult mouse ventricular cardiac myocytes was simulated by
modifying experimental protocols described for different species 230-233.
First, a glucose-free modified tyrode solution (110 mM NaCl, 2.6 mM KCl,
1.2 mM KH2PO4, 1.2 mM MgSO4, 1 mM CaCl2, 10 mM HEPES, pH 7.4) was
gassed with 95% N2 and 5% CO2 for 30 min.  The anoxic solution was kept at
37°C in a tightly closed syringe (1 ml).  Then the dishes were carefully washed
three times with a glucose-free modified tyrode solution (110 mM NaCl,
2.6 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 1 mM CaCl2, 10 mM HEPES,
pH 7.4).  After completion of the last wash the anoxic glucose-free tyrode solution
was quickly released into the dish, which was immediately placed in gas tight
chambers of own design (Figure 6).  The chambers were closed fast and the
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cardiac myocytes were incubated at 37°C in an environment of 95% N2 and
5% CO2 for 4, 8, and 12 hours.
Reoxygenation was achieved by switching to medium 199 and incubation with
21% O2, 74% N2, and 5% CO2 at 37°C for 4 hours.  Time matched control
myocytes were incubated in an environment of 21% O2, 74% N2, and 5% CO2 at
37°C.
Figure 6.  Setup for experiments of simulated ischemia.  Anoxia chambers (A) are
perfused with 95% N2  and 5% CO2.  Normoxia chambers (B) are perfused with
21% O2, 74% N2, and 5% CO2.  Note that the bottom of all chambers is filled with
water to ensure sufficient humidity.  Both gas mixtures are humidified separately
(C).  The gas outlets are placed in a beaker (D) filled with water column of 10 cm
to visually control the flow rate and to prevent a back stream of room air.
The activities of lactate dehydrogenase (LDH) and creatine kinase (CK) in the
supernatant were determined after simulated ischemia, reoxygenation and lysis
of the cells with 1% TritonX-100 (Sigma).  Therefore, at each timepoint the
supernatant was carefully taken from each dish, collected in a 1.5 ml
microcentrifuge tube (500PP, Greiner), and centrifuged 2000 rpm for 5 min.
Then two 300 µl samples of supernatant of each tube were carefully taken,
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collected in 1.5 ml microcentrifuge tubes, immediately frozen in liquid nitrogen,
and stored at –80°C until further analysis.  The remaining volume of the initial
supernatant contained a few broken cardiac myocytes and cellular debris and
was discarded in order not to disturb the measurements.  For lysis of the cells
medium 199 with Triton-X (1% final concentration) was applied to the cells. The
dishes were then placed on a shaker (Schüttler MTS4, IKA) and gently moved at
200 rpm for 30 min.
The release of enzymes was calculated as the percentage of activity after
ischemia / reoxygenation versus total activity (simulated ischemia +
reoxygenation + TritonX-100 extracts).  The activities of LDH and CK were
determined by a Hitachi 917 Automatic Analyzer (Hitachi) according to methods
of the German Society for Clinical Chemistry 1970 234 and 1993 235, respectively.
The hearts of six FGF–1 transgenic mice and six nontransgenic control mice were
used per timepoint of simulated ischemia.
4.3. Determination of a Flow-Pressure-Relationship
The hearts of eight FGF–1 transgenic mice and of seven nontransgenic
littermates used as control mice were quickly dissected, cannulated through the
ascending aorta and retrogradely perfused as described above (chapter 2.1).
Thereafter, the catheter was connected to a perfusion apparatus of own design,
which allowed a pressure and temperature controlled retrograde perfusion of the
mouse heart.  Perfusion buffer was supplemented with 0.01% adenosine to
achieve maximal vasodilation and kept at a temperature of 37°C.  Four different
perfusion pressures were applied: 80 mmHg, followed by 100, 122, and
142 mmHg for 10 minutes each.
The coronary perfusates were collected in 50 ml tubes (Falcon).  After
centrifugation at 2000 rpm the volume of the coronary perfusate was determined.
Finally, the hearts were weighed on a scientific scale (BP 211 D, Sartorius).  The
coronary flow was expressed in terms of milliliters of coronary perfusate per
150 mg of heart weight.
Preliminary experiments showed that addition of BSA or any other protein to the
perfusion buffer was not necessary.  The coronary flow at 80 mmHg was the same
before and after the regular 40 min perfusion period indicating that no vascular
leakage, possibly due to a lack of protein in the perfusion buffer, occurred.
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4.4. Femoral Artery Occlusion and Blood Flow
Measurements
Mice were anesthetized by injection (i.p.) of a mixture of ketamine (10 %,
Medistar) and xylazine (Serum-Werk Bernburg AG).  The right femoral artery
was ligated proximal to the orifices of the arteria poplitea but distal to the
branching-point of the arteria profunda femoris (Figure 7).  Blood flow
measurements were performed before, immediately after, three, seven, 21, and
28 days after occlusion, using the same anesthesia protocol.  At the end of the
study the mice were euthanized and the descending thoracic aortas were
cannulated for subsequent perfusion fixation of the hindlimbs.
A red Laser Doppler Imager (MLDI 5063, Moor Instruments Ltd.) was used to
detect blood cell motion in the foot to estimate relative blood flow.  Relative score
of vessels were compared after the background subtracting.
Preliminary experiments showed that blood flow results obtained by LDI are
dependent on the ambient temperature.  Therefore, in order to standardize
measurements, anesthetized mice were kept for 5 min in a climatized chamber of
own design at 37°C before the measurements were performed.  Special care was
taken that the measured paws were clean and dry.
Blood flow measurements by LDI were performed in sedentary FGF–2 transgenic
and nontransgenic control mice on following time points: before right femoral
artery occlusion, immediately thereafter and on days 3, 7, 14, 21, 28, and 39 after
occlusion.  Trained mice were only measured before, immediately after, and
39 days after the initial surgery to avoid disturbance of the exercise protocol due
to the anesthesia.  The last training session was completed at day 36 to ensure a
full recovery of two days before the final measurements.  LDI measurements of
the whole feet were made at a pixel resolution of 256x256 and at a scan rate of
4 ms/pixel for a 1.7 by 3 cm area.  Dead mice were used to determine the
background level separately for each strain for subsequent subtraction. The
right-to-left, i.e. occluded-to-nonoccluded side, perfusion ratios were calculated
for each timepoint and mouse (Figure 8).
To determine gastrocnemius blood flow by MRI a flow phantom consisting of four
tubes connected in series with inner diameters of 0.40 mm, 0.58 mm, and two of
1.46 mm was evaluated in an eight-leg 2.8 cm diameter by 3.2 cm length lowpass
birdcage coil.  Sufficiently long tubing between the flow tubes allowed for
equilibration of exited spins before entering the detection and excitation plane.
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Figure 7.  A) Acute occlusion (arrowhead) of the left femoral artery.  Note the
preexisting superficial collateral arterioles (arrow).  B) Growing collateral arteries
(arrow) seven days after occlusion of the right femoral artery (arrowhead).  The
collateral arteries grow in both diameter and length resulting in the typical
corkscrew growth pattern.
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Figure 8.  Representative time course of foot blood flow recovery after right
femoral artery occlusion of a Balb/C mouse determined by Laser Doppler Imaging
(LDI).  A) immediately before occlusion, B) immediately after occlusion, C) three
days, D) seven days, E) 14 days, and F) 21 days after occlusion of the right
femoral artery.
Time-of-flight images were acquired in a Bruker PharmaScan 70/16 7.0 Tesla
imager for a square field of view of 1.28 cm for a two-dimensional matrix of
128x128.  Slice planes of 0.62 mm, 1 mm, and 1.5 mm were acquired
perpendicular to the axially flow of aqueous 1.0 mmol/l copper sulfate solution
used to simulate T1 and T2 for blood.  Flow rates were changed by altering the
height of a supply water reservoir and restricting the water outflow.  Linear flow
through the three tubes of different diameters was calculated by measuring the
mass of solution for the determined time period.  The acquisition of the image
plane was done by acquiring single lines in k-space every 23 ms with 90° pulses
and echo times of 8 ms.  In a steady state with no flow, a loss of magnetization is
observed due to the fast repetition time and large pulse angle.  However, under
conditions of inflowing fluid the magnetization is determined by the amount of
fluid that enters the slice between detection pulses.  The theoretical maximum
occurs when the linear flow equals or exceeds the length of the detection slice per
unit of time between detection slices.  For laminar flow this does not hold true
since the fluid in the center of the tube moves at a much faster rate than near the
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walls.  This can be observed in images with slow flow rates.  The intensity in the
center volume is higher than the edges.  In nonlinear tortuous vessels streaming
has also been characterized and observed.  The smaller tubes of the flow phantom
showed similar effects.  Streaming occurred preferential at the edges of the tubes.
Increasing slice thickness results in phase artifacts from greater field
inhomogenities, manifested as concentric rings in the cross-section.  These
artifacts, however, did not significantly affect the results at the slow flow rates.
Gastrocnemius blood flow was determined at day 39 after femoral artery
occlusion.
At the end of the study all mice were euthanized.  The thorax was opened and the
descending aorta was cannulated as described for the ascending aorta (see
chapter 4.1).  Then the catheter was connected to a perfusion apparatus of own
design, which allowed a pressure and temperature controlled perfusion of the
distal vessels.  The perfusion buffer was supplemented with 0.01% adenosine to
achieve vasodilation.  The distal vessels were perfused with perfusion buffer at a
temperature of 37°C and a pressure of 100 mmHg until they were free of blood.
Afterwards, both hindlimbs were perfusion-fixed with 2% paraformaldehyde in
perfusion buffer for 10 minutes at a pressure of 100 mmHg.
Following perfusion fixation a contrast medium (bismuth chloride in 5% gelatin)
was infused and the hindlimbs were immersed in ice.  Angiographies were
acquired using a Machlett-Balteau X-ray source (set at 20 kV /8 mA).  Superficial
collateral arteries visible under the operating microscope were photographed and
sampled for ultrastructural studies and histological analysis.  Furthermore,
skeletal muscle samples containing the deep collateral arteries and the
gastrocnemius muscles were sampled for histological analysis.  The postmortem
angiographies were individually evaluated by two independent observers
unaware of the sample identities.
4.5. Training of Mice with Unilateral Femoral Artery
Occlusion
Two days after unilateral occlusion of the femoral artery 12 FGF–2 transgenic
animals and their 12 nontransgenic littermates that were used as control mice
were randomly separated into six sedentary mice and six mice that were trained
for five weeks.  The mice were trained using a progressive, moderate intensity
endurance running regime on the mouse treadmill as follows:
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Day 0: Occlusion of the right femoral artery.
Day 1: Rest.
Day 2: Rest.
Day 3: Running at an inclination of 9° and a speed of 10 m/min for 30 min.
Day 4: Running at an inclination of 9° and a speed of 11 m/min for 35 min.
Day 5: Running at an inclination of 9° and a speed of 12 m/min for 40 min.
Day 6: Rest.
Day 7: Running at an inclination of 9° and a speed of 13 m/min for 45 min.
Day 8: Running at an inclination of 9° and a speed of 14 m/min for 50 min.
Day 9: Running at an inclination of 9° and a speed of 15 m/min for 55 min.
Day 10: Running at an inclination of 9° and a speed of 16 m/min for 55 min.
Day 11: Running at an inclination of 9° and a speed of 17 m/min for 60 min.
Day 12: Running at an inclination of 9° and a speed of 18 m/min for 60 min.
Day 13: Rest.
Day 14: Running at an inclination of 9° and a speed of 19 m/min for 60 min.
Day 15: Running at an inclination of 9° and a speed of 20 m/min for 60 min.
Day 16: Running at an inclination of 9° and a speed of 21 m/min for 60 min.
Day 17: Running at an inclination of 9° and a speed of 22 m/min for 60 min.
Day 18: Running at an inclination of 9° and a speed of 23 m/min for 60 min.
Day 19: Running at an inclination of 9° and a speed of 24 m/min for 60 min.
Day 20: Rest.
Day 21: Running at an inclination of 9° and a speed of 25 m/min for 60 min.
Day 22: Running at an inclination of 9° and a speed of 25 m/min for 60 min.
Day 23: Running at an inclination of 9° and a speed of 25 m/min for 60 min.
Day 25: Running at an inclination of 9° and a speed of 25 m/min for 60 min.
Day 26: Running at an inclination of 9° and a speed of 25 m/min for 60 min.
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Day 27: Running at an inclination of 9° and a speed of 30 m/min for 60 min.
Day 28: Rest.
Day 29: Running at an inclination of 9° and a speed of 25 m/min for 60 min.
Day 30: Running at an inclination of 9° and a speed of 25 m/min for 60 min.
Day 31: Running at an inclination of 9° and a speed of 25 m/min for 60 min.
Day 32: Running at an inclination of 9° and a speed of 25 m/min for 60 min.
Day 33: Running at an inclination of 9° and a speed of 25 m/min for 60 min.
Day 34: Running at an inclination of 9° and a speed of 30 m/min for 60 min.
Day 35: Rest.
Day 36: Determination of exercise capacity.
Day 37: Rest.
Day 38: Rest.
Day 39: Final measurements and tissue harvesting.
The first exercise session was initiated at day 3 post ligation.  The inclination
was set to 9° and a speed of 10 m/min was chosen.  The first exercise session
lasted for 30 min.  Thereafter, the speed and the duration were increased by
1 m/min and 5 min, respectively, until the mice were able to run up a
9° inclination at a speed of 25 m/min for 60 min (Figure 9).  This level was
achieved at day 21 of the study.  During the first week, the mice were submitted
to three consecutive exercise sessions followed by one day of rest.  From there on,
mice were trained six times per week followed by one day of rest.  After the mice
were capable to run at the final workload, the day before the day of rest was used
for a more strenuous exercise session at a speed of 30 m/min.  If a mouse
exhibited signs of fatigue the exercise session was terminated.  The final exercise
capacity was determined at day 36 of the study after one day of rest.  Thereafter,
the animals were allowed to recover for two days before the final measurements
of blood flow by LDI and MRI, angiography, and tissue harvesting.
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Figure 9.  Typical exercise session of FGF–2 transgenic mice and nontransgenic
control mice with unilateral femoral occlusion.  The mice are running at an
inclination of 9° and a speed of 25 m/min for 60 min.
4.6. Determination of Exercise Capacity
4.6.1. Time Course after Bilateral Femoral Artery Occlusion
Prior experiments revealed that mice with bilateral femoral artery occlusion are
not able to perform the standard exercise test until seven days after the initial
operation.  Therefore, determination of the time course of exercise capacity
changes after bilateral femoral artery occlusion was started seven days after the
initial operation and was repeated every seven days until day 28.
All mice were initially familiarized with the treadmill.  During the week before
the operation they ran up an inclination of 3° at a speed of 10 m/min for 10 min.
This was repeated twice after a break of one day.
The exercise protocol consisted of a graded running test on a mouse treadmill of
own design (Figure 10), partially adopted from a rabbit treadmill of the physics
workshop of the University of Melbourne in Australia.  Each mouse initially ran
up a 6° inclination at a speed of 20 m/min for 15 minutes (Figure 11).  Thereafter,
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the treadmill speed was increased by 5 m/min every 15 minutes until the animal
reached the point of fatigue.  The criterion used to determine fatigue was the
inability of the mouse to keep pace with the treadmill.  If the animal had lost its
righting reflex, the end-point of fatigue was confirmed.  The time from beginning
of the exercise to the removal of the mouse from the treadmill was recorded.
The exercise tests were repeated every seven days until day 28 post-ligation.  The
same protocol was used for non-ligated control animals.  At the end of the
exercise test the performed work for each animal was calculated and expressed in
Joule (J) as follows:
work (J) = body mass of animal (kg) × run distance (m) × [1 + 9.81m/s2 × sine of inclination (°)]
(for calculation see also 236).
Figure 10.  Experimental setup for determination of exercise capacity. (A)
treadmill-speed controller, (B) rodent treadmill, (C) electrical stimulation box
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Figure 11.  Exercise test of a Balb/C mouse.  The mouse is running in the initial
stage of the exercise test protocol (inclination of 6° and a speed of 20 m/min) on
the rodent treadmill.
4.6.2. Time Course after the Onset of Congestive Heart Failure
The protocol of the exercise test used for MCP–1 transgenic mice was similar to
the protocol described above (chapter 4.6.1.) with the exception that the first
exercise test was performed at the age of 16 weeks.  Thereafter, the tests were
repeated every four weeks until all transgenic mice had died due to congestive
heart failure.  The same protocol was used for their nontransgenic littermates
that served as control mice.
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4.6.3. Trained Mice with Unilateral Femoral Artery Occlusion
FGF–2 transgenic animals and their nontransgenic littermates that used as
control mice were randomly separated into sedentary mice and mice that were
trained for five weeks.  The exercise test was performed at day 36 after the initial
operation.  The protocol of the exercise test used for these mice was similar to the
protocol described above (chapter 4.6.1.) with the exception that the inclination of
the treadmill was 9°.
4.7. Statistical Analysis
After all data were analyzed for normal distribution and variance homogeneity a
one–way analysis of variance (ANOVA) or a Student-Newman-Kuels post-hoc
analysis revealed the significance of the groups differences.  Differences at the
p<0.05 level were considered significant.
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5. Results
5.1. Simulated Ischemia
The release of LDH and CK from cardiac myocytes is caused by the loss of cell
membrane integrity and is a sign of cell death.  In clinical chemistry, both
enzymes are used as markers of damage and death of various cell types including
cardiac myocytes.  The activity of these enzymes in the serum of patients
provides valuable diagnostic tools for determination of the severity of myocardial
infarction.
Creatine kinase release of FGF–1 transgenic myocytes was significantly
decreased at four hours of simulated ischemia when compared to nontransgenic
myocytes (10.86 ± 1.38% vs. 33.14 ± 2.26%, respectively, Figure 12, Table 1).  At
eight hours of simulated ischemia the release of CK of transgenic myocytes was
still reduced when compared to nontransgenic myocytes (42.33 ± 1.99% vs.
60.48 ± 2.95%, respectively).  However, at 12 hours of simulated ischemia there
was no statistically significant difference between the CK release of transgenic
and nontransgenic myocytes (76.65 ± 0.80% vs. 71.03 ± 1.53%, respectively).
Under normoxic conditions there was no significant change in the release of CK
of transgenic myocytes when compared with nontransgenic myocytes
(2.54 ± 0.35% vs. 3.27 ± 0.37%, respectively) during the 16 hour experimental
protocol.
Table 1. CK release of nontransgenic control myocytes and FGF–1 transgenic
ventricular cardiac myocytes during 4h, 8h, and 12h of simulated
ischemia and during the 16 hour experimental protocol under
normoxic conditions.
Time point Nontransgenic FGF–1 Transgenic
Normoxia 16h
Ischemia 4h
Ischemia 8h
Ischemia 12h
3.27 ± 0.37%
33.14 ± 2.26%
60.48 ± 2.95%
71.03 ± 1.53%
2.54 ± 0.35%
10.86 ± 1.38%*
42.33 ± 1.99%*
76.65 ± 0.80%
Data are means ± SEM. * p < 0.05 vs. same time point of nontransgenic myocytes.
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Figure 12.  CK release of nontransgenic control myocytes and FGF–1 transgenic
ventricular cardiac myocytes during 4h, 8h, and 12h of simulated ischemia and
during the 16h experimental protocol under normoxic conditions.  Data are
means ± SEM. * p < 0.05 vs. same time point of nontransgenic myocytes.
Similar to the release of CK, LDH release of transgenic myocytes was decreased
at four hours of simulated ischemia when compared to nontransgenic myocytes
(33.59 ± 2.51% vs. 58.64 ±  3.02% respectively, Figure 13, Table 2).  This
difference was still apparent at eight hours of simulated ischemia (73.94 ± 3.18%
vs. 86.87 ± 3.46%, respectively).  However, at 12 hours of simulated ischemia the
release LDH from transgenic myocytes was not significantly different when
compared to LDH release from nontransgenic myocytes (90.98 ± 3.37% vs.
90.85 ± 1.56%, respectively).
Similar to the release of CK, the basal LDH release of transgenic and
nontransgenic myocytes under normoxic conditions during the 16 hours of the
experimental protocol was not significantly different (35.24 ±  1.86% vs.
34.69 ± 2.58%, respectively).
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Table 2. LDH release of FGF–1 transgenic ventricular cardiac myocytes and
nontransgenic control myocytes during 4h, 8h, and 12h of simulated
ischemia and during the 16h experimental protocol under normoxic
conditions.
Time point Nontransgenic FGF–1 Transgenic
Normoxia 16h
Ischemia 4h
Ischemia 8h
Ischemia 12h
34.69 ± 2.58%
58.64 ± 3.02%
86.87 ± 3.46%
90.85 ± 1.56%
35.24 ± 1.86%
33.59 ± 2.51%*
73.94 ± 3.18%*
90.98 ± 3.37%
Data are means ± SEM. * p < 0.05 vs. same time point of nontransgenic myocytes.
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Figure 13.  LDH release of FGF–1 transgenic ventricular cardiac myocytes and
nontransgenic control myocytes during 4h, 8h, and 12h of simulated ischemia and
during the 16h experimental protocol under normoxic conditions.  Data are
means ± SEM. * p < 0.05 vs. same time point of nontransgenic myocytes.
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5.2. Determination of a Flow-Pressure-Relationship
There was no statistically significant difference in heart weight of FGF–1
transgenic mice when compared to nontransgenic control mice.  The average
heart weight was 150 mg.  Therefore, the coronary flow was expressed in terms of
milliliters of coronary perfusate per 150 mg of heart weight.  The hearts of
FGF–1 transgenic animals displayed a significantly increased coronary flow at
all the pressures tested when compared to nontransgenic control mice.  At a
pressure of 80 mmHg coronary flow of transgenic hearts was
1.10 ± 0.04 ml/min/150mg (increased by 17%) while nontransgenic hearts had a
coronary flow of 0.94 ± 0.05 ml/min/150mg (Figure 14, Table 3).  At 100 mmHg
coronary flow of transgenic hearts was increased by 19% when compared to
nontransgenic hearts (1.46 ± 0.09 ml/min/150 mg vs. 1.23 ± 0.05 ml/min/150 mg,
respectively).  At 122 mmHg coronary flow of transgenic hearts was increased by
24% compared to nontransgenic hearts (1.81 ± 0.10 ml/min/150 mg vs.
1.46 ± 0.03 ml/min/150 mg, respectively).  At 142 mmHg the increase in coronary
flow of transgenic hearts was 33% when compared to nontransgenic hearts
(2.14 ± 0.19 ml/min/150 mg vs. 1.61 ± 0.001 ml/min/150 mg, respectively).
The slope of the regression function corresponding to FGF–1 transgenic hearts
was increased by 36% (b=0.0152) when compared to the slope of the regression
function of nontransgenic hearts (b=0.0112) (Figure 15).  The slope of the
regression function for change in flow (∆flow) was significantly different from 0
(b=0.0040), demonstrating an elevated pressure-dependent increase in coronary
flow of transgenic hearts.
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Table 3. Coronary flow of nontransgenic controls and FGF–1 transgenic
hearts at four different pressures (80, 100, 122, and 142 mmHg).
Coronary Flow
(ml/min/150 mg) at
Nontransgenic FGF–1 Transgenic
80 mmHg
100 mmHg
122 mmHg
142 mmHg
0.94 ± 0.05
1.23 ± 0.05
1.46 ± 0.03
1.61 ± 0.001
1.10 ± 0.04*
1.46 ± 0.09*
1.81 ± 0.10*
2.14 ± 0.19*
Data are means ± SEM. * p < 0.05 vs. nontransgenic hearts.
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Figure 14.  Coronary flow of nontransgenic control hearts (NTG) and FGF–1
transgenic hearts (TG) at four different pressures (80, 100, 122, and 142 mmHg).
Data are means ± SEM. * p < 0.05 vs. nontransgenic hearts.
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Figure 15.  Regression curves of coronary flow vs. pressure of nontransgenic
control hearts (wt) and FGF–1 transgenic hearts (L1) at four different pressures
(80, 100, 122, and 142 mmHg).  (∆ flow = change in coronary flow between
transgenic and nontransgenic hearts)
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5.3. FGF–2 Transgenic Mice with Unilateral Femoral Artery
Occlusion
5.3.1. Progressive, Moderate Intensity Endurance Exercise Program
The intensity of the endurance exercise program was considered moderate
because the mice did not exhibit signs of fatigue during the individual sessions.
Signs of fatigue include frequent contacts with the grid (more than one contact
per minute) and gait change to a gallop with exaggerated hops.  Only during the
two more strenuous exercise sessions (day 27 and day 34) some animals exhibited
signs of fatigue by the end of the exercise session.  These mice were removed from
the treadmill and the program was completed in order to apply a strenuous
stimulus to all mice.
A progressive character was chosen because it has been observed before that the
exercise capacity of mice with bilateral femoral artery occlusion is dramatically
reduced during the first week but recovers within 3 weeks to approximately 60%.
The mice completed the first sessions without problems.  In their cages the mice
did not use their occluded leg for walking during the first week.  However, while
running on the treadmill the mice were forced to use the occluded leg properly.
During the first week the mice were limping occasionally, especially at the end of
the exercise session.  During the second week of the exercise regime limping was
observed less frequently and it disappeared during the third week.  After the
third week no difference in the leg motion between the occluded leg and the
normal leg was observed.
It appeared that the occluded leg was darker and had a slightly blue color after
the exercise sessions when compared to the normal leg.  This effect was neither
observed prior the exercise sessions in trained mice or in sedentary mice.
Interestingly, the change in color persisted over the period of the experiment.
The occluded leg looked different from the normal leg after each exercise session.
5.3.2. Collateral Dependent Blood Flow
Collateral dependent blood flow to the foot was determined by LDI.  At day 39
post occlusion trained FGF–2 transgenic mice displayed significantly improved
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foot blood flow when compared to sedentary nontransgenic and trained
nontransgenic mice (0.97 ± 0.03 vs. 0.66 ± 0.10, 0.78 ± 0.06, respectively,
Figure 16, Table 4).  Sedentary FGF–2 transgenic mice showed a trend towards
improved foot blood flow compared to sedentary nontransgenic mice (0.88 ± 0.06
vs. 0.66 ± 0.10, respectively).  However, this trend did not achieve the level of
significance.
0.0
0.2
0.4
0.6
0.8
1.0
1.2
NTG Sedentary NTG Trained TG Sedentary TG Trained
Bl
oo
d 
flo
w 
(rig
ht/
lef
t ra
tio
)
*
Figure 16.  Collateral dependent blood flow to the foot (determined by LDI) of
sedentary nontransgenic (NTG Sedentary), trained nontransgenic (NTG Trained),
sedentary FGF–2 transgenic (TG Sedentary), and trained FGF–2 transgenic (TG
Trained) mice at day 39 post occlusion.  Data are means ± SEM. * p < 0.05 vs.
sedentary nontransgenic mice.
Gastrocnemius blood flow of the occluded leg determined by MRI (Figure 18)
revealed a significant increase in trained and sedentary transgenic mice when
compared to sedentary nontransgenic mice (0.85 ± 0.06, 0.85 ± 0.10 vs.
0.60 ± 0.06, respectively, Figure 17, Table 4).  Gastrocnemius blood flow of
trained nontransgenic mice was similar to sedentary nontransgenic mice
(0.61 ± 0.10 vs. 0.60 ± 0.06, respectively).  However, changes in gastrocnemius
blood flow of the normal leg were different from the changes observed in the
occluded leg.  There was a stepwise increase in blood flow from sedentary
nontransgenic to trained nontransgenic to sedentary FGF–2 transgenic to
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trained FGF–2 transgenic mice (0.83 ± 0.06, 0.93 ± 0.07, 1.00 ± 0.15, 1.16 ± 0.11,
respectively).  However, the only mice that demonstrated significantly increased
gastrocnemius blood flow of the normal leg were the trained FGF–2 transgenic
mice.
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Figure 17.  Collateral dependent blood flow to the gastrocnemius (determined by
MRI) of sedentary nontransgenic, trained nontransgenic, sedentary FGF–2
transgenic, and trained FGF–2 transgenic mice at day 39 post occlusion (R=right
occluded leg, L=left normal leg).  Data are means ± SEM. * p < 0.05 vs. sedentary
nontransgenic mice.
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Figure 18.  Representative cross-sectional Magnetic Resonance Images (MRI) of
A) a sedentary nontransgenic mouse, B) a sedentary FGF–2 transgenic mouse,
C) a trained nontransgenic mouse, and D) a trained FGF–2 transgenic mouse.
Note the three main arteries (arrows) of the gastrocnemius (RG=right
gastrocnemius (occluded leg), LG=left gastrocnemius (normal leg)).  The tubes for
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determination of the standard flow are marked by the arrowheads.  Structures in
lower part of the images represent the caudal part of the mouse including the tail
artery and veins.
Table 4. Collateral dependent blood flow to the foot determined by Laser
Doppler Imaging and to the gastrocnemius determined by Magnetic
Resonance Imaging of sedentary nontransgenic, trained
nontransgenic, sedentary FGF–2 transgenic, and trained FGF–2
transgenic mice.
Blood Flow Sedentary
Non-
Transgenic
Trained
Non-
Transgenic
Sedentary
FGF–2
Transgenic
Trained
FGF–2
Transgenic
LDI of Foot
(right/left ratio) 0.66 ± 0.10 0.78 ± 0.06 0.88 ± 0.06 0.97 ± 0.03*
MRI of
Gastrocnemius
(ml/min/g)
Occluded leg
MRI of
Gastrocnemius
(ml/min/g)
Normal leg
0.60 ± 0.06
0.83 ± 0.06
0.61 ± 0.10
0.93 ± 0.07
0.85 ± 0.10*
1.00 ± 0.15
0.85 ± 0.06*
1.16 ± 0.11*
Data are means ± SEM. * p < 0.05 vs. nontransgenic sedentary mice.
5.3.3. Exercise Capacity
Exercise capacity of trained FGF–2 transgenic mice was significantly increased
when compared to trained nontransgenic mice, sedentary FGF–2 transgenic
mice, and sedentary nontransgenic mice (139.17 ± 11.12 J vs. 99.08 ± 9.07 J,
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50.95 ± 2.73 J, 45.10 ± 4.19 J, respectively, Figure 19, Table 5).  Exercise capacity
of trained FGF–2 transgenic and trained nontransgenic mice increased by 208%
and 120%, respectively, when compared to sedentary nontransgenic mice.  There
was no statistically significant difference between sedentary transgenic and
sedentary nontransgenic mice.
Trained nontransgenic and trained FGF–2 transgenic mice were running without
visible limitation by the occluded leg.  However, both sedentary groups were
impaired in their performance by the occlusion of the right femoral artery.  This
effect was characterized by limping of the right hindlimb and by making contact
with the right wall of the treadmill lane in which the mouse was running.
Table 5. Exercise capacity of sedentary nontransgenic, sedentary FGF–2
transgenic, trained nontransgenic, and trained FGF–2 transgenic
mice at day 36 after occlusion of the right femoral artery.
Exercise Capacity
Influenced by:
Genotype:
Nontransgenic
Genotype:
FGF–2 Transgenic
Activity:
Sedentary 45.10 ± 4.19 J 50.95 ± 2.73 J
Activity:
Trained 99.08 ± 9.07 J* 139.17 ± 11.12 J**
Data are means ± SEM.* p < 0.05 vs. nontransgenic sedentary mice,
** p < 0.05 vs. nontransgenic trained mice.
5.3.4. Gastrocnemius Weight-to-Body Weight Ratio
Right gastrocnemius weight-to-body weight ratio of sedentary nontransgenic
mice was significantly decreased by 15% when compared to the normal left side
(7.19 ± 0.43 mg/g vs. 8.45 ± 0.42 mg/g, respectively, Figure 20, Table 6).  Right
gastrocnemius weight-to-body weight ratio of trained nontransgenic mice was
significantly decreased by 14% when compared to the normal left side
(7.37 ± 0.10 mg/g vs. 8.57 ± 0.28 mg/g, respectively).
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Figure 19.  Exercise capacity of sedentary nontransgenic (NTG Sedentary),
trained nontransgenic (NTG Trained), sedentary FGF–2 transgenic (TG
Sedentary), and trained FGF–2 transgenic (TG Trained) mice at day 36 after
occlusion of the right femoral artery.  Data are means ± SEM.  * p < 0.05 vs.
nontransgenic sedentary mice, ** p < 0.05 vs. nontransgenic trained mice.
Table 6. Gastrocnemius-to-body weight ratio of sedentary nontransgenic,
trained nontransgenic, sedentary FGF–2 transgenic, and trained
FGF–2 transgenic mice.
Gastrocnemius-to-Body Weight
Ratio
Right
Gastrocnemius
(mg/g)
Left
Gastrocnemius
(mg/g)
Sedentary Nontransgenic 7.19 ± 0.43* 8.45 ± 0.42
Trained Nontransgenic 7.37 ± 0.10* 8.57 ± 0.28
Sedentary FGF–2 Transgenic 7.34 ± 0.44 7.79 ± 0.33
Trained FGF–2 Transgenic 7.29 ± 0.15 7.93 ± 0.41
Data are means ± SEM. * p < 0.05 vs. left gastrocnemius of same group.
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There was no statistically significant difference between the right and left
gastrocnemius weight-to-body weight ratios of sedentary FGF–2 transgenic mice
(7.34 ± 0.44 mg/g vs. 7.79 ± 0.33 mg/g, respectively).  Similarly, the right and left
gastrocnemius weight-to-body weight ratios of trained FGF–2 transgenic mice
were not significantly different (7.29 ± 0.15 mg/g vs. 7.93 ± 0.41 mg/g,
respectively).  The difference in left gastrocnemius weight-to-body weight ratio
between all groups was not statistically significant.  However, a trend towards a
lower left gastrocnemius weight-to-body weight ratio of the two transgenic groups
was noted.
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Figure 20.  Gastrocnemius-to-body weight ratio of sedentary nontransgenic
(NT Sedentary), trained nontransgenic (NTG Trained), sedentary FGF–2
transgenic (TG Sedentary), and trained FGF–2 transgenic (TG Trained) mice.
Data are means ± SEM.  * p < 0.05 vs. left gastrocnemius of same group
Postmortem angiographies of sedentary nontransgenic and FGF–2 transgenic
mice demonstrated the typical corkscrew growth pattern of collateral arteries
(Figure 21).  Collateral arteries of sedentary FGF–2 transgenic mice appeared to
be slightly bigger than those of sedentary nontransgenic mice.  Trained
nontransgenic mice displayed more diffuse angiographies with numerous smaller
vessels and were lacking the corkscrew growth pattern.  Similarly, trained
FGF–2 transgenic mice demonstrated a diffuse picture.  However, even more
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smaller vessels were apparent.  These vessels were contributed over the entire
proximal hindlimb.  Even though the typical corkscrew growth pattern was
lacking and the precise origins and ends of these vessels were sometimes difficult
to determine, they still appeared to serve as collateral connections passing the
site of occlusion.
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Figure 21.  Representative angiographies of A) sedentary nontransgenic mice, B)
sedentary FGF–2 transgenic mice, C) trained nontransgenic mice, and D) trained
FGF–2 transgenic mice.  Note the site of occlusion (arrowhead) and the typical
corkscrew growth pattern of the collateral arteries in sedentary mice (arrow).
Trained nontransgenic mice display a dense collateral network with numerous
smaller vessels.  Trained FGF–2 transgenic mice show a diffuse growth pattern
with the highest vessel density of all groups.
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5.4. Determination of Exercise Capacity
5.4.1. Time Course after the Onset of Congestive Heart Failure
At the age of 16 weeks, exercise capacity of MCP–1 transgenic mice was
significantly reduced by 38% when compared to nontransgenic control mice
(72.45 ± 5.63 J vs. 117.47 ± 10.00 J, respectively, Figure 22, Table 7).  At the age
of 20 weeks, the same difference was apparent (36% reduction) with both MCP–1
transgenic and nontransgenic mice displaying approximately the same exercise
capacity determined initially (71.55 ± 6.08 J vs. 112.55 ± 16.60 J, respectively).
At the age of 24 weeks, exercise capacity of MCP–1 transgenic mice was reduced
by 42% when compared to nontransgenic mice (59.12 ± 6.74 J vs. 102.11 ± 7.38 J,
respectively).  At week 28 exercise capacity of nontransgenic animals was
100.45 ± 8.97 J.  Five of the remaining seven MCP–1 transgenic mice had died
due to congestive heart failure caused by chronic myocarditis.  The two surviving
mice displayed symptoms of severe heart failure including dyspnea at rest and
massive edema.  One transgenic mouse died one minute after initiation of the
exercise test.  The other transgenic mouse was not able to start running and no
attempt was made to submit the mouse to a complete exercise test.  After the
sudden death of the first mouse and after the observation that the second mouse
was not able to perform any work, the thorax’ of these mice were opened
immediately.  Massive ventricular and atrial hypertrophy was observed.  The
ventricles appeared to be enlarged approximately 2 fold while the atria seemed to
be even bigger than that compared to hearts of nontransgenic mice.
Table 7. Exercise capacity of nontransgenic control mice and MCP–1
transgenic mice at the age of 16, 20, 24, and 28 weeks.
Exercise Capacity Nontransgenic MCP–1 Transgenic
16 weeks
20 weeks
24 weeks
28 weeks
117.47 ± 10.00 J
112.55 ± 16.60 J
102.11 ± 7.38 J
100.45 ± 8.97 J
72.45 ± 5.63 J*
71.55 ± 6.08 J*
59.12 ± 6.74 J*
/
Data are means ± SEM. * p < 0.05 vs. nontransgenic mice.
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Figure 22.  Exercise capacity of nontransgenic control mice (NTG) and MCP–1
transgenic mice (TG) at the age 16, 20, 24, and 28 weeks. Data are means ± SEM.
* p < 0.05 vs. nontransgenic mice.
Both mice had severe ascites and pulmonary congestion.  The slight decrease in
exercise capacity of nontransgenic mice over the experimental period of 16 weeks
was not statistically significant.  At each time point tested the MCP–1 transgenic
mice exhibited stronger signs of fatigue after the exercise test when compared to
nontransgenic animals.  A characteristic drop of water forming under the nose of
the mouse at the end of the exercise test was observed frequently in MCP–1
transgenic mice.  In nontransgenic mice this drop was observed but less frequent.
The loss of the righting reflex was found in every transgenic animal and lasted
longer than in nontransgenic mice.  After the test transgenic mice displayed
pronounced dyspnea.  The phase of voluntary inactivity after the exercise test
was longer than that of nontransgenic mice.
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5.4.2. Time Course after Bilateral Femoral Artery Occlusion
Collateral dependent blood flow to the foot determined by LDI revealed a
significant increase in blood flow over a period of four weeks post occlusion.  The
major changes occurred within the first 2 weeks.  The next two weeks were
characterized by only minor changes in collateral dependent blood flow to the
foot.  Balb/C mice demonstrated the least increase in foot blood flow after femoral
artery occlusion.  Right-to-left ratio increased from 0.01 ± 0.01 immediately after
occlusion to 0.05 ± 0.01 at day 3, to 0.21 ± 0.05 at day 7, to 0.37 ± 0.06 at day 14,
remained unchanged at day 21 (0.36 ± 0.05), and increased to 0.51 ± 0.07 at
day 28 (Figure 23, Table 8).  Collateral dependent blood flow to the foot of sv129
mice increased significantly more during the study period.  Immediately after
occlusion right-to-left ratio was already 0.16 ± 0.05 and increased to 0.34 ± 0.10
at day 3, to 0.62 ± 0.09 at day 7, to 0.83 ± 0.09 at day 14, to 0.81 ± 0.09 at day 21,
to 0.92 ± 0.12 at day 28 post occlusion.  The fastest increase in collateral
dependent blood flow to the foot was observed in C57Bl/6 mice.  Right to left ratio
increased from 0.10 ± 0.03 immediately after occlusion to 0.36 ± 0.08 at day 3, to
Table 8. Collateral dependent blood flow to the foot determined by LDI of
Balb/C, sv129, and C57Bl/6 mice with unilateral femoral artery
occlusion immediately before and after occlusion, and at days 3, 7,
14, 21, and 28.
Blood Flow
(Right/left ratio)
Balb/C sv129 C57Bl/6
Before
After
Day 3
Day 7
Day 14
Day 21
Day 28
0.98 ± 0.06
0.01 ± 0.01
0.05 ± 0.01
0.21 ± 0.05
0.37 ± 0.06
0.36 ± 0.05
0.51 ± 0.07
0.96 ± 0.02
0.16 ± 0.05
0.34 ± 0.10
0.62 ± 0.09*
0.83 ± 0.09*
0.81 ± 0.09*
0.92 ± 0.12*
0.97 ± 0.02
0.10 ± 0.03
0.36 ± 0.08*
0.73 ± 0.06*
0.97 ± 0.04*
1.03 ± 0.04*
1.02 ± 0.04*
Data are means ± SEM. * p < 0.05 vs. Balb/C mice.
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 Figure 23. Collateral dependent blood flow to the foot (right/left ratio)
determined by LDI of Balb/C, sv129, and C57Bl/6 mice with unilateral femoral
artery occlusion immediately before and after occlusion and at days 3, 7, 14, 21,
and 28.  Data are means ± SEM. * p < 0.05 vs. Balb/C.
0.73 ± 0.06 at day 7, to 0.97 ± 0.04 at day 14, and remained unchanged at day 21
(1.03 ± 0.04) and at day 28 (1.02 ± 0.04).
Determination of exercise capacity revealed a significant difference between
normal Balb/C (102.91 ±  6.59 J) and sv129 as well as C57Bl/6 mice
(72.87 ± 6.49 J and 70.91 ± 3.46 J, respectively, Figure 24, Table 9).  At day seven
after bilateral femoral artery occlusion there was no significant difference in
exercise capacity between Balb/C, sv129 and C57Bl/6 mice (26.13 ± 3.46 J vs.
21.20 ± 1.58 J vs. 23.30 ± 3.23 J, respectively).  At day 14 post occlusion the
exercise capacities of mice of the three different strains were again similar
(42.58 ± 5.97 J vs. 37.03 ± 4.44 J vs. 41.73 ± 4.78 J, respectively).  No significant
change in exercise capacity could be observed at day 21 after occlusion when
comparing Balb/C, sv129 and C57Bl/6 mice (48.20 ± 3.31 J vs. 48.20 ± 4.64 J vs.
45.71 ± 3.95 J, respectively).  There was little change in exercise capacity during
the fourth week after bilateral femoral artery occlusion and the difference
between the three strains still did not reach the level of significance
(49.02 ± 3.59 J vs. 48.67 ± 4.74 J vs. 46.38 ± 4.07 J, respectively).
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Table 9. Exercise capacity of unoperated Balb/C, sv129, and C57Bl/6 mice
and at days 7, 14, 21, and 28 after bilateral femoral artery occlusion.
Exercise
Capacity
Balb/C sv129 C57Bl/6
Control
Day 7
Day 14
Day 21
Day 28
102.91 ± 6.59 J*
26.13 ± 3.46 J
42.58 ± 5.97 J
48.20 ± 3.31 J
49.02 ± 3.59 J
72.87 ± 6.49 J
21.20 ± 1.58 J
37.03 ± 4.44 J
48.20 ± 4.64 J
48.67 ± 4.74 J
70.91 ± 3.46 J
23.30 ± 3.23 J
41.73 ± 4.78 J
45.71 ± 3.95 J
46.38 ± 4.07 J
Data are means ± SEM. * p < 0.05 vs. sv129 and C57Bl/6 mice.
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 Figure 24.  Exercise capacity of unoperated Balb/C, sv129, and C57Bl/6 mice
and at days 7, 14, 21, and 28 after bilateral femoral artery occlusion.  Data are
means ± SEM. * p < 0.05 vs. sv129 and C57Bl/6 mice.
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However, when exercise capacity of mice with bilateral femoral artery occlusion
was blotted as the percentage of unoperated control mice significant differences
in the recovery of exercise capacity could be observed.  When comparing the
recovery of exercise capacity of Balb/C, sv129 and C57Bl/6 mice at day seven post
occlusion a trend towards an increase was observed (25.39 ± 3.36% vs.
29.09 ± 2.17% vs. 32.86 ± 4.56%, respectively, Figure 25, Table 10).  At day 14
this trend became statistically significant for C57Bl/6 mice when compared to
Balb/C (58.85 ± 6.74% vs. 41.38 ± 5.80%, respectively).  The recovery of exercise
capacity of sv129 mice was 50.82 ± 6.09%, which was not significantly different
from the two other strains.  At day 21 post occlusion a significant difference
between Balb/C versus sv129 and C57Bl/6 was observed (46.84 ± 3.22% vs.
66.15 ± 6.37% vs. 64.46 ± 5.57%, respectively).  This difference was still apparent
at day 28 with only a slight increase in recovery of exercise capacity of each
strain (47.63 ± 3.49% vs. 66.79 ± 6.50% vs. 65.41 ± 5.74%, respectively).
Exercise tests at days 7 and 14 post ligation demonstrated a severe limitation of
the performance of all mice by the bilateral femoral artery occlusion.  The point
of fatigue was determined if the animal was only dragging their hindlimbs and
not properly moving them.  However, exercise tests at days 21 and 28 showed a
gain in function of the hindlimbs at the end of the test.  The limitation of
performance could not exclusively be ascribed to femoral artery occlusion.  When
compared to control mice there was still a difference in the behavior on the
treadmill especially at the end of the test.
Table 10. Recovery (% of control mice) of exercise capacity of Balb/C, sv129,
and C57Bl/6 mice with bilateral femoral artery occlusion at days 7,
14, 21, and 28.
Exercise
Capacity
Balb/C sv129 C57Bl/6
Control
Day 7
Day 14
Day 21
Day 28
100.00 ± 6.40%
25.39 ± 3.36%
41.38 ± 5.80%
46.84 ± 3.22%
47.63 ± 3.49%
100.00 ± 8.91%
29.09 ± 2.17%
50.82 ± 6.09%
66.15 ± 6.37%*
66.79 ± 6.50%*
100.00 ± 4.88%
32.86 ± 4.56%
58.85 ± 6.74%*
64.46 ± 5.57%*
65.41 ± 5.74%*
Data are means ± SEM. * p < 0.05 vs. Balb/C mice.
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 Figure 25.  Recovery (% of control mice) of exercise capacity of Balb/C, sv129,
and C57Bl/6 mice with bilateral femoral artery occlusion at days 7, 14, 21, and
28 post occlusion.  Data are means ± SEM. * p < 0.05 vs. Balb/C mice.
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6. Discussion
6.1. Simulated Ischemia
A study conducted in our laboratory 64 demonstrated that mice with cardiac-
specific overexpression of FGF–1 display a marked cardioprotection when
submitted to myocardial infarction induced by ligation of the left coronary artery
(see also chapter 3.1.5.).  However, infarct development was only delayed and not
prevented by overexpression of FGF–1.  This suggested that a direct protective
effect of FGF–1 on cardiac myocytes was responsible for these findings rather
than the increase in the density of small arterioles demonstrated in another
study 48.  There exists a direct relation between the amount of permanently
salvaged myocardium and collateral flow.  Since permanent salvage was not
achieved we concluded that collateral vessels did not contribute to the increased
arteriolar density.  However, to undoubtedly prove that FGF–1 overexpression
increased the tolerance of cardiac myocytes towards ischemia we conducted the
experiments of simulated ischemia.
When isolated cardiac myocytes were submitted to simulated ischemia, cell
viability of transgenic cardiac myocytes was increased at the first two of three
time points.  CK and LDH are two commonly used enzymes and their release
from cells is indicative of cell death.  Similar to our in vivo study, the
cardioprotective effect of FGF–1 occured during the early time points.  At 4 hours
of simulated ischemia CK release from nontransgenic control myocytes was
increased approximately 10 fold when compared to the CK release under
normoxic conditions during the 16 hours of the experimental protocol.
Transgenic myocytes on the other hand increased the CK release only 4 fold,
indicating a markedly enhanced viability of transgenic myocytes.  This effect was
still apparent at 8 hours of simulated ischemia.  However, the protective effect of
FGF–1 overexpression on cardiac myocyte viability was abolished at 12 hours of
simulated ischemia.  The release of CK of nontransgenic and transgenic cardiac
myocytes was similar at 12 hours of simulated ischemia.
When LDH was used as a marker of cell death, similar results were obtained.
Interestingly, transgenic cardiac myocytes did not release more LDH at 4 hours
of simulated ischemia when compared to the basal release under normoxic
conditions during the 16 hours of the experimental period.  This suggests that
4 hours of simulated ischemia caused very little damage.  However, the increased
CK release at 4 hours compared to the basal release demonstrates that it would
be an underestimation to state that 4 hours of simulated ischemia did not cause
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any cell damage.  Nontransgenic control myocytes increased the LDH release at
the same time point by approximately 60%, showing a clear increase in cell
death.  At 8 hours of simulated ischemia nontransgenic control myocytes
displayed significantly increased LDH release when compared to transgenic
myocytes.  The difference between the LDH release of nontransgenic and
transgenic myocytes was smaller but still statistically significant.  Again, at
12 hours of simulated ischemia, no difference in LDH release between
nontransgenic and transgenic cardiac myocytes was observed, indicating a loss of
the cardioprotective effect at later time points.
Both markers of cell death revealed a strong cardioprotective effect of FGF–1
overexpression on isolated ventricular cardiac myocytes.  The effect was most
pronounced at the earliest time point of simulated ischemia.  The protective
effect decreased at 8 hours of simulated ischemia but was still prominent and
statistically significant.  However, FGF–1 overexpression could only delay but
not abolish the damaging effects of simulated ischemia as indicated by similar
release of cell death markers at 12 hours.
These in vitro findings closely resemble the situation found in vivo.  Therefore,
we conclude that cardiac-specific overexpression of FGF–1 delays infarct
development in vivo and increases the tolerance of isolated cardiac myocytes
towards simulated ischemia.  The results of the in vitro experiments demonstrate
that the delayed infarct development was caused by cardiac myocytes, which
display enhanced viability under ischemic conditions.  We could show with these
experiments that the increased density of small arteries and arterioles did not
provide any protective effect and thus, was not the reason for the observed delay
in infarct development.
Our findings are in accordance with a recently published study that investigated
the cardioprotective effect of FGF–2 on hearts of mice overexpressing FGF–2 237.
Similar to our model of cardiac-specific overexpression of FGF–1 no significant
effect on heart weight-to-body weight ratio was noted.  FGF–2 overexpression
resulted in a 20% increase in capillary density.  Thus, FGF–1 and FGF–2 exert
different effects considering the growth of capillaries and of arterioles and small
arteries.  The investigators utilized an isolated mouse heart model of ischemia-
reperfusion to access the cardioprotective effect of FGF–2 overexpression.  The
LDH release of transgenic and nontransgenic mouse hearts was determined in
the perfusate.  A significantly decreased release from transgenic hearts was
found during the reperfusion period, indicating a strong cardioprotective effect of
FGF–2.  However, this study accessed only the cardioprotective effect of FGF–2
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during 30 minutes of ischemia followed by 60 minutes of reperfusion.
Investigating more time points and evaluating the total release of LDH during
the reperfusion period could have revealed more information.  Nevertheless, it is
evident that cardiac-specific overexpression of FGF–1 as well as FGF–2 exert
strong cardioprotective effects.
The aforementioned results proved our initial hypothesis and were therefore very
valuable.  However, this study revealed other interesting details that were
previously not described in the literature.  The basal release of LDH for example,
was higher when compared to the basal release of CK.  If taken as the only
marker, one would think that, in the case of CK, only approximately 3% of the
cells die under normoxic conditions during the 16 hours of the experimental
protocol.  However, under the same conditions the basal release of LDH was
much higher when compared to the release of CK.  The LDH release of
approximately 35% under normoxic condition during the 16 hours of the
experimental protocol suggests that about one third of all cardiac myocytes die
during the control period.
Frequent microscopic evaluation of the dishes revealed that the basal LDH
release most likely reflects the actual number of dead cells.  After 12 hours of
anoxia, only a fairly small percentage of myocytes was still rod-shaped and had
intact cell membranes.  Again, LDH release appeared to reflect the situation
better than CK release.
The fact that approximately one third of all myocytes dies under normoxic
conditions during the 16 hours of the experimental period is easy to explain and
no surprise.  Adult ventricular cardiac myocytes are extremely fragile and
sensitive cells that have very stringent requirements on culture media,
temperature, oxygen tension, etc..  Since the used medium lacks any growth
factors and no FCS was added, the cardiac myocytes were not kept under optimal
conditions.  Therefore, it is not surprising that approximately one third of all
myocytes died within the control period.
The observation that the release of CK and LDH from isolated ventricular
cardiac myocytes submitted to the same experimental condition differs, has not
been described before.  This suggests that the release of CK displays a different
kinetic.  The cause of this difference has to be clarified.  Differences in molecular
weight and different structural features might be of importance but this remains
a matter of speculation until further studies are conducted.  However, these
observations are of importance for following studies and for comparisons of
different studies using these two markers of cell damage and death.
6. Discussion - 92 -
In conclusion, the experiments of simulated ischemia demonstrated that
ventricular cardiac myocytes isolated from adult mice with cardiac specific-
overexpression of FGF–1 show a marked delay in cell death when compared to
nontransgenic control myocytes.  This suggests that overexpression of FGF–1
exerts a cardioprotective effect.  However, the cardioprotection delays but does
not abolish cell death due to simulated ischemia.  These experiments provided an
explanation for the in vivo finding of a delayed infarct development in transgenic
mice.  The marker that most accurately reflected the microscopic evaluation of
the dishes was the release of LDH.  The difference between the release of LDH
and CK is pronounced and requires careful interpretation of studies using either
one of these markers.
6.2. Determination of a Flow-Pressure-Relationship
Investigating the effects of cardiac-specific FGF–1 overexpression on capillary
and arterial growth in the heart 48, we found an increase in the number of
arterioles and small arteries.  Furthermore, the number of branches of the main
coronary arteries was significantly increased in transgenic animals.  There was
no change in the number of capillaries.  We hypothesized that the increased
number of arterioles would lead to an increase in coronary flow of intact
transgenic mouse hearts.  Therefore, we accessed the coronary flow by ex vivo
retrograde perfusion of the heart under maximal vasodilatory conditions at four
different pressures.
The established flow-pressure-relationship demonstrated that the increase in
arteriolar density is reflected by an enhanced myocardial perfusion.
Furthermore, the difference in coronary flow between transgenic and
nontransgenic mice increased with the perfusion pressure, resulting in a
significant pressure-dependent increase in coronary flow of transgenic mice.  This
suggests that the increase in the arteriolar density could have important
physiological consequences.  However, the significance of an enhanced coronary
flow, especially at higher pressures, in the in vivo situation remains to be
determined.
The determination of the flow-pressure-relationship of mice overexpressing
FGF–1 revealed that increased branching of the main coronary arteries and an
increase in the number of arterioles and small arteries is capable of changing the
myocardial perfusion.
6. Discussion - 93 -
The isolated heart preparation for determination of the coronary flow in order to
reflect vascular growth was recently used by another group of investigators 238.
The pressure-flow relationship was established in a slightly different manner
than in our experiments.  Instead of using different perfusion pressures and
monitoring the amount of coronary effluent, these investigators controlled the
coronary inflow rate and monitored the required pressure to achieve a certain
coronary flow.  The angiogenic effect of PR39, a 39 amino acid peptide secreted by
macrophages, was reflected by a shift to the left of the pressure-flow curve.  The
findings that an increase in the number of vessels increases the coronary flow are
similar to our results even tough they were obtained with slightly different
methods.
However, the linear relationship between the applied pressure and the resulting
coronary flow was not accessed in the aforementioned study.  Our study revealed
that the increase in the number of resistance vessels in the hearts of transgenic
mice was reflected by a steeper inclination of the pressure-flow curve.  Therefore,
we observed at higher pressures a greater difference in coronary flow between
transgenic and nontransgenic mouse hearts.
It appears that our model of investigating the coronary flow via establishing a
pressure-flow relationship is accurate and suitable for determination of the
functional relevance of an increase in the number of small arteries and arterioles
in hearts overexpressing FGF–1.  The pressure-flow curves reveal important
details about the dynamic change of the coronary flow in response to increased
perfusion pressures.  Therefore, the established protocol is valuable for future
studies investigating changes of the coronary vasculature.
6.3. FGF–2 Transgenic Mice with Unilateral Femoral Artery
Occlusion
The progressive, moderate intensity endurance exercise program was well
tolerated by all mice and induced significant morphological, hemodynamic, and
functional changes in trained mice.  These changes were more pronounced in
mice with a general overexpression of FGF–2.  This study revealed interesting
details about the functional significance of the exercise program on one hand and
of FGF–2 overexpression on the other hand.
Sedentary mice overexpressing FGF–2 increased the hindlimb perfusion of the
occluded leg determined by MRI compared to nontransgenic sedentary control
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mice.  The normal leg displayed slightly (not statistically significant) elevated
blood flow.  The increase in right-to-left ratio determined by LDI did not achieve
the level of significance.  Thus, the increase in hindlimb blood flow due to FGF–2
overexpression in sedentary mice was at the level of borderline significance.
These findings were reflected by the exercise capacity.  Sedentary FGF–2
transgenic mice displayed a small increase in exercise capacity that did not
achieve the level of significance when compared to sedentary nontransgenic mice.
It would be interesting to see whether the difference in exercise capacity between
transgenic and nontransgenic mice would be more pronounced if determined in
mice with bilateral femoral artery occlusion.  Possibly, the limiting effect of
bilateral femoral artery occlusion would be so severe that the small increase in
blood flow in transgenic mice would lead to a significant increase in exercise
capacity.  However, this remains a matter of speculation until clarifying
experiments are carried out.
Surprisingly, nontransgenic mice with unilateral femoral artery occlusion that
were submitted to the progressive, moderate intensity endurance exercise
program increased their exercise capacity by approximately 120% compared to
their sedentary counterparts.  Hindlimb perfusion of trained nontransgenic mice
determined by two different methods was insignificantly less when compared to
sedentary transgenic mice.  However, since the difference in exercise capacity
between the two sedentary groups was small, trained nontransgenic animals
increased their exercise capacity also by about 100% when compared to sedentary
transgenic mice.
Thus, a fairly small increase in hindlimb perfusion of sedentary FGF–2
transgenic mice lead to a similar, insignificant increase in exercise capacity.
However, blood flow levels between that of sedentary nontransgenic and
transgenic mice were not reflected by exercise capacity in trained nontransgenic
mice.  The training program was causing a significant increase in exercise
capacity without exerting a major effect on resting hindlimb blood flow.
There was a significant increase in hindlimb blood flow determined by LDI
between trained nontransgenic and transgenic mice.  However, determination of
blood flow by MRI did not reveal significant differences.  Therefore, we
considered the blood flow difference between the two trained groups to be at the
level of borderline significance.  However, determination of exercise capacity
uncovered the significance of increase in blood flow due to overexpression of
FGF–2.  Trained transgenic mice displayed a significant 40% increase in exercise
capacity when compared to trained nontransgenic mice.  When compared to
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sedentary nontransgenic mice, trained FGF–2 transgenic mice increased exercise
capacity by approximately 200%.
One could speculate that the significant difference in exercise capacity between
the two trained groups arises from adaptations due to the endurance exercise
program.  The increased exercise capacity compared to the sedentary groups can
in part be explained by the full range of metabolic alterations due to training (for
review see 100).  With the advanced skeletal muscle metabolism during exercise
the enhanced blood supply becomes a limiting factor.  Then, trained transgenic
mice have the advantage of a better blood flow, which is now responsible for a
significant difference in exercise capacity.
Another contributing factor to the increased exercise capacity could be an altered
pattern of vascular growth.  Angiographic observations showed that trained mice
form a dense collateral network.  The typical corkscrew collateral arteries
developed only in sedentary mice.  It is possible that trained mice have developed
a skeletal muscle vasculature that efficiently supplies blood to the whole
hindlimb especially during exercise.  It seems that the corkscrew growth pattern
is capable of increasing calf blood flow and foot blood flow during resting
conditions to a certain extent so that no ischemia is present.  However, this
corkscrew growth pattern might not be sufficient to meet the blood flow needs
during exercise, especially of the muscles of the thigh.
Currently, we perform histological studies to precisely determine the vascular
growth pattern.  We investigate skeletal muscle tissue from the proximal
hindlimb where collateral arteries developed (arteriogenesis) and from the distal
hindlimb where possibly angiogenesis occurred.  Analysis of these skeletal
muscle samples will provide us with information whether the increased vessel
density observed in the angiograms is due to growth of the preexistent collateral
vessels in diameter or due to increased arteriolar development and growth.  We
will determine the extent of angiogenesis in the gastrocnemius and we will
investigate the roles of overexpression of FGF–2 and of the endurance exercise
program with possible treatment interactions.
It would be of great interest to determine hindlimb blood flow during exercise.
Unfortunately, until now we did not succeed to develop a precise system for
determination of exercise blood flow.  However, similar studies of Terjung and
colleagues provide valuable information.
In 1998, they conducted a study in rats investigating the effect of intra arterial
FGF–2 infusion via osmotic minipumps 185.  Subgroups of the FGF–2 group and
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the carrier group were trained for four weeks twice daily until the point of fatigue
was reached.  They determined the hindlimb blood flow at the end of contractility
tests.  Therefore, blood flow measurements can be considered to reflect exercise
blood flow.  Similar to our study, a stepwise increase in total hindlimb blood flow
from the sedentary carrier group to the trained carrier group to the sedentary
FGF–2 group and to the trained FGF–2 group was found.  The total hindlimb
blood flow of the trained FGF–2 group was significantly greater than all other
groups.  Proximal hindlimb blood flow showed similar results.  Distal blood flow
of the trained carrier group, sedentary FGF–2 group, and trained FGF–2 group
were significantly increased compared to the sedentary carrier group.  Tension
development of the calf muscles showed similar results compared to our exercise
capacity results.  Even though blood flow of the trained carrier group was
(insignificantly) lower than blood flow of the sedentary FGF–2 group the opposite
was true for the developed tension.  Similar to our results, muscle performance of
the trained FGF–2 group was by far the greatest.  Therefore, one could speculate
that blood flow levels during exercise in our model would be similar to the resting
blood flow levels possibly with increased absolute values and greater differences
between the groups.  The order, however, would probably stay the same.
Our study demonstrated that trained mice generally overexpressing FGF–2
display an increased exercise capacity when compared to all other groups.  This
finding opposes the results reported in the aforementioned study 185.  In this
study no significant difference in total running time was observed.  However, for
determination of exercise capacity we did not just record total running time of
training sessions but performed a precise and reproducible exercise test.
Furthermore, contractile performance of trained rats with FGF–2 infusion was
significantly better when compared to all other groups.  It’s hard to imagine that
the improved contractile performance together with the increased blood flow
would not lead to increased exercise capacity under controlled conditions as used
in our study.
That trained animals display a significantly increased skeletal muscle blood flow
during exercise is shown by another recent study 187.  Rats with prior training to
bilateral femoral artery occlusion show a markedly increased skeletal muscle
blood flow during exercise when compared to sedentary control rats.  A previous
study of the same investigators 177 indicates that rats with bilateral femoral
artery occlusion, which were then trained for up to eight weeks, increase
hindlimb blood flow during exercise significantly when compared to sedentary
control animals.  Unfortunately, these studies did not determine resting blood
flow levels because the investigators did probably not expect any difference.
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The current understanding is that exercise uncovers latent ischemia in the heart
as well as in limbs.  Nevertheless, our resting blood flow measurements
determined by MRI and LDI do show differences.  However, only the trained
FGF–2 transgenic mice demonstrated a significant increase in blood flow
determined by both methods.  The magnitude of the differences between the
other groups is smaller.  Statistically significant results are only observed by one
of the methods or not at all.  Therefore, we can only speculate that resting blood
flow measurements reflect to some extent the predicted exercise blood flow
measurements.  Furthermore, blood flow levels during exercise would probably
give rise to a greater difference between the groups.
As described in chapter 5.3.3., the occluded leg of trained mice did not display
any functional limitation during the test.  This indicated that the blood supply of
the occluded hindlimb during exercise was fairly normal and/or that metabolic
adaptations developed leading to proper function despite a limited blood supply.
Interestingly, FGF–2 overexpression abolished gastrocnemius atrophy due to
occlusion of the femoral artery.  A significant difference between left and right
gastrocnemius weight-to-body weight ratio was only observed in nontransgenic
mice.  Endurance exercise did not influence the gastrocnemius weight-to-body
weight ratios.  The atrophy of the right gastrocnemius could have been a limiting
factor for exercise capacity of trained nontransgenic animals, leading to a
significant decrease when compared to the exercise capacity of trained FGF–2
transgenic mice.
These findings confirm one of the earliest studies investigating the effect of
endurance exercise on development of the collateral circulation 97.  Among other
results (see also chapter 3.3.) the study demonstrated that femoral artery
occlusion causes atrophy of the distal muscles, which is not influenced by an
endurance exercise program alone.  Many years later, we could now show that
overexpression of FGF–2 abolishes distal skeletal muscle atrophy due to femoral
artery occlusion.  The protective effect of FGF–2 on cells submitted to
ischemia 237 could be one of the reasons for this effect.  Other explanations
involve the angiogenic effect of FGF–2.  Better capillary supply of the individual
skeletal muscle fibers of the distal hindlimb in FGF–2 transgenic mice could lead
to less ischemia and thus, less atrophy.
The slightly decreased gastrocnemius weight-to-body weight ratio of the normal
leg of transgenic mice is most likely due to the reduction in bone length caused by
overexpression of FGF–2 228.
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Preliminary experiments performed in our laboratory could aid in understanding
the mechanism by which trained transgenic animals were able to increase
skeletal muscle blood flow as well as exercise capacity significantly.  Our initial
hypothesis was that training of FGF–2 transgenic mice would lead to a promoter-
dependent increase in expression of the transgene.  The promoter of
phosphoglycerate kinase was used for construction of the transgene.  Since this
enzyme is a part of glycolysis, we hypothesized that acceleration of glycolysis due
to exercise would in turn increase the expression of FGF–2.  Furthermore, the
phosphoglycerate kinase gene contains a binding element for HIF–1 in its
promoter region 239 and HIF–1 expression has been shown to increase in
response to exercise 111.
However, preliminary results obtained by Northern blots of phosphoglycerate
kinase 1 do not support our initial hypothesis.  We did not observe a clear
increase in phosphoglycerate kinase 1 expression due to exercise.  Nevertheless,
we could see increased levels of phosphoglycerate kinase in transgenic animals.
The expression patterns between nontransgenic and FGF–2 transgenic mice were
also different.  The significance of these findings remains to be determined.  We
currently perform Northern blots of FGF–2 to investigate whether the expression
levels of phosphoglycerate kinase and FGF–2 correlate.  Furthermore, we will
study FGF–2 at the protein level by Western blot analysis.  The enhanced release
of intracellular FGF–2 in response to stress (exercise) could have increased the
amount of FGF–2 in the extracellular space.  Therefore, it is possible that trained
FGF–2 transgenic mice display enhanced vascular growth due to the increased
availability of FGF–2 in the extracellular space.
However, other mechanisms could have also contributed to the observed increase
in blood flow and exercise in trained FGF–2 transgenic mice.  Exercise for
example could have increased shear stress in the collateral circulation, simply
providing an additional stimulus for arteriogenesis in the FGF–2 transgenic
mice.  Another possible explanation could be that overexpression of FGF–2 could
have multiplied the growth factor response to exercise (see also chapters 3.1. and
3.3.).
In conclusion, our study demonstrates that trained mice with unilateral femoral
artery occlusion overexpressing FGF–2 display increased hindlimb blood flow and
exercise capacity.  FGF–2 abolished the gastrocnemius atrophy due to femoral
artery occlusion.  Training did not influence gastrocnemius atrophy.
Angiographic observations show the formation of a dense vascular network in
trained FGF–2 transgenic mice.  Future studies will uncover the mechanism of
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this treatment interaction and reveal histological details about the changed
vascular growth pattern in trained FGF–2 transgenic mice.
6.4. Determination of Exercise Capacity
6.4.1. Time Course After the Onset of Congestive Heart Failure
Mice with cardiac specific overexpression of MCP–1 displayed already at an age
of 16 weeks moderate exercise intolerance as one of the main symptoms of heart
failure patients.  At an age of 20 weeks exercise capacity remained reduced by
the same magnitude when compared to nontransgenic mice.  At 24 weeks of age
exercise capacity of MCP–1 transgenic mice was decreased by 42%, which was an
additional reduction of 6% compared to the month before.
However, during this period of time no major change in exercise capacity
occurred.  Unexpectedly, signs of exercise intolerance were already found at an
age of 16 weeks.  The presence of this major symptom of heart failure indicates
that deleterious cardiac changes had already occurred.  The lack of other
symptoms like visible congestion and resting dyspnea suggests that heart failure
was at a compensated stage.
During the next eight weeks no major changes in exercise capacity were noted
indicating that progression of heart failure was slowly.  However, between
weeks 24 and 28 of age, five of the seven remaining mice died due to heart
failure.  Symptoms then included severe congestion and dyspnea at rest.  These
findings demonstrate progression of heart failure from the compensated to the
decompensated stage.  The two remaining mice were severely impaired in their
ability to perform work.  They also displayed severe congestion and resting
dyspnea as signs of end-stage congestive heart failure.  The facts that one mouse
died during the test and that the other remaining mouse could not even start the
test illustrate the severity and the progression of heart failure between weeks 24
and 28.
The observed ventricular and atrial hypertrophy was massive and developed
mainly during the last weeks of the study period.  Hearts taken at the beginning
of the study and at an age of 20 weeks did not show signs of hypertrophy, while
the heart taken at 24 weeks of age was already moderately hypertrophied.
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These observations demonstrate that cardiac-specific overexpression of MCP–1
leads to chronic myocarditis 94 resulting in the development of congestive heart
failure.  At an age of 16 weeks, exercise intolerance was present as the first sign
of heart failure.  Thereafter, a slow progression of heart failure was noted
without severe worsening of exercise intolerance.  Between 24 and 28 weeks of
age, cardiac-specific overexpression of MCP–1 led to a sudden and homogeneous
switch from the compensated to the decompensated heart failure stage.  This
resulted first in visible congestion, resting dyspnea, and severe exercise
intolerance and later in death of the animals.  Mice with decompensated heart
failure showed ascites, pulmonary congestion, and massive ventricular and atrial
hypertrophy.
Histological examination of the hearts taken at each time point of the study is
currently performed in our laboratory and will reveal the degrees of myocarditis,
monocyte infiltration, fibrosis, and hypertrophy of ventricular and atrial cardiac
myocytes.
Another interesting experiment to perform in the future would be to study the
effect of different endurance exercise programs on the development of CHF.  Low,
moderate, and high intensity endurance exercise programs exert different kinds
of stress on the heart.  The model of cardiac-specific overexpression of MCP–1
mimics closely the human form of CHF due to chronic myocarditis.  Therefore,
this study could reveal important information for human patients considering the
effect of exercise on progression or regression of CHF.  A low intensity endurance
exercise program could hypothetically exert a beneficial influence on myocarditis,
leading to regression of CHF.  A high intensity endurance exercise program could
possibly worsen myocarditis and CHF.  Since very few studies exist that are
providing conclusive information about this topic these hypotheses are very
speculative and in need of experimental prove.  Treating subgroups of mice with
MCP–1 antibodies and/or CCR2 blockers would provide even more information.
In conclusion, cardiac-specific overexpression of MCP–1 induces myocarditis
causing the homogenous development of CHF.  The determination of exercise
capacity has proven to be a precise marker for the limitation of cardiac function
in CHF.  We could demonstrate that, without the presence of other symptoms
like visible congestion and resting dyspnea, moderate exercise intolerance was
present at an age of 16 weeks, indicative of a compensated stage of CHF.  The
switch from the compensated to the decompensated CHF stage occurs between 24
and 28 weeks of age of MCP–1 transgenic mice.  Visible congestion and resting
dyspnea are additional symptoms, which become apparent during this period.
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Exercise capacity was then severely impaired, resulting either in death of the
mouse during the exercise test or inability to run at the initial level of the test.
Massive cardiac and atrial hypertrophy in combination with severe ascites and
pulmonary congestion illustrate the development of decompensated CHF.
6.4.2. Time Course after Bilateral Femoral Artery Occlusion
Measurements of collateral dependent foot blood flow by LDI give rise to relative
numbers, which indicate that foot blood flow of the occluded leg is at the level of a
certain percentage of foot blood flow of the normal leg.  LDI measurements
revealed that Balb/C mice increased collateral dependent foot blood flow only to
51% during four weeks after femoral artery occlusion.  Collateral dependent foot
blood flow of sv129 mice increased significantly during the same period when
compared to Balb/C mice.  After four weeks foot blood flow of the occluded leg
increased to 92% of the normal leg.  C57Bl/6 mice displayed an even faster and
stronger recovery in collateral dependent foot blood flow.  These mice had a foot
perfusion of 97% after two weeks.
We hypothesized that these remarkable differences in the recovery of foot blood
flow would lead to similar differences in the recovery of exercise capacity.  In
order to establish the recovery of exercise capacity as a marker of the increase in
collateral dependent foot blood flow, we had to make sure that femoral artery
occlusion severely influences exercise capacity.  Therefore, we bilaterally
occluded the femoral artery of six mice of each strain.  Results obtained seven
days after occlusion indicate that a severe limitation of exercise capacity was
exerted by bilateral femoral artery occlusion.
However, to compare the relative blood flow data with the results from the
exercise tests, we had to express these data in relative units as well.  For this
purpose, we determined the exercise capacity of six control mice of each strain
without femoral artery occlusion and set this number to 100%.  Exercise capacity
of each time point was then expressed as the percentage of exercise capacity of
control mice without femoral artery occlusion.
While Balb/C mice with bilateral femoral artery occlusion were able to increase
their exercise capacity during four weeks only to 48%, sv129 and C57/Bl6 mice
showed a recovery of 69% and 65%, respectively.  Similar to the faster increase in
foot blood flow, C57Bl/6 mice increased exercise capacity to 59% after two weeks.
However, the recovery of exercise capacity did not even reach 70% in any of the
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strains.  Even though sv129 and C57Bl/6 mice recovered foot blood flow to
approximately 100%, the recovery of exercise capacity was markedly less.
Therefore, the results of the present study indicate that the recovery of collateral
dependent resting foot blood flow is only partially reflected by the recovery of
exercise capacity.  Mice with the greatest recovery in blood flow (sv129 and
C57Bl/6) demonstrate the greatest improvement in exercise capacity.  However,
their recovery in exercise capacity levels off at 68% to 65%, respectively, even
though they entirely recover foot blood flow.  Accordingly, mice with the smallest
recovery in foot blood flow (Balb/C) show the smallest recovery in exercise
capacity.
These observations give rise to several possible explanations.  One explanation
involves the significance of the resting foot blood flow measurements by LDI for
skeletal muscle blood flow during exercise.  Even though we observed in C57Bl/6
a total recovery of collateral dependent foot blood flow, this does not necessarily
mean that skeletal muscle blood flow during exercise had increased to the same
extend.  Moreover, it is possible that skeletal muscle blood flow during exercise
remained decreased when compared to control animals without femoral artery
occlusion.
A study in rats performed by Yang et al. 177 points into this direction (see also
chapter 6.3.).  In their study not even rats with femoral artery occlusion trained
for up to eight weeks were able to recover skeletal muscle blood flow to a level
similar to control rats without occlusion of the femoral artery.  The difference
became especially apparent when the rats were running at high treadmill speeds.
Trained rats with occlusion of the femoral artery showed only approximately 50%
skeletal muscle blood flow during high-intensity exercise when compared to
control rats.  The difference was less during low-intensity exercise.  Thus, it is
possible that mice are capable to increase resting foot perfusion to 100% while
skeletal muscle blood flow during high-intensity exercise is significantly
decreased.
Therefore, future studies considering the relationship between the recovery of
blood flow and the recovery of exercise capacity are in need of the determination
of skeletal muscle blood flow during exercise.  However, adaptation of the
methods currently used for evaluation of blood flow will take some time and
certain technical difficulties will have to be overcome.  It is, nevertheless, worthy
to do so because this technique can be used for other studies (see also chapter
6.3.).
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Skeletal muscle blood flow measurements during exercise could provide
information about a possible correlation of exercise capacity with skeletal muscle
blood flow.  It would be interesting to see if skeletal muscle blood flow during
exercise is in better agreement with exercise capacity than resting foot blood flow
determined by LDI.  An endurance exercise program is able to increase skeletal
muscle blood flow during exercise 177 and increases exercise capacity as well.  If a
correlation could be established, the real importance of skeletal muscle blood flow
for exercise capacity could be uncovered.
One of the first observations of this study was the difference in the initial
exercise capacity between the three strains expressed in absolute numbers (work
in Joule).  Normal Balb/C mice display the highest absolute exercise capacity
followed by sv129 mice.  C57Bl/6 mice displayed an absolute exercise capacity
that was only slightly less than that of sv129 mice.  This strain dependent
difference of absolute exercise capacity could not be explained by any of the above
mentioned observations.  These findings provide material for future studies
regarding anatomical and metabolic changes of mice of different strains leading
to increased absolute exercise capacity.
Similarly, the reason for the difference in the recovery of collateral dependent
blood flow is not presently known.  Postmortem angiographies performed in our
laboratory have recently shown that Balb/C mice display the typical corkscrew
growth pattern of collateral arteries.  Angiographies from sv129 and C57Bl/6
mice show a more diffuse picture of the developing collateral circulation.  The
angiographic findings suggest that Balb/C mice have a limited ability to grow and
recruit more arteries for the blood supply of the hindlimb.  It appears that they
have to rely on the preexistent collateral arterioles and only the increase in
diameter of these vessels provides the blood supply for the distal hindlimb.  Thus,
growth of a few collateral connections in size leads to angiographies with well
visible collateral arteries in the typical corkscrew pattern.  Especially C57Bl/6
mice that have the capacity to grow numerous arteriolar connections display
rather diffuse angiographies without well visible collateral arteries in the typical
corkscrew pattern.
These assumptions are in accordance with the recent angiographic findings of our
study investigating the effect of general overexpression FGF–2 and endurance
exercise (see also chapter 6.3.).  Trained FGF–2 transgenic mice demonstrated
the best gastrocnemius and foot blood flow and displayed diffuse angiographies.
Sedentary nontransgenic mice with the worst perfusion had well visible collateral
arteries in the typical corkscrew growth pattern.
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However, the significance of these observations remains unclear.  Therefore,
histological analysis of the hindlimb tissue has to reveal the precise differences in
collateral growth pattern.  Differential gene expression arrays could indicate key
genes responsible for the different recovery in collateral dependent blood flow.
In conclusion, our study provides evidence that different strains of mice with
femoral artery occlusion display a different recovery of collateral dependent foot
blood flow under resting conditions.  This observation is reflected by a similar
pattern of the recovery of exercise capacity, which does not reach the extent of
the recovery in foot blood flow.  C57Bl/6 mice demonstrate the best recovery of
foot blood flow and exercise capacity.  Compared to the other strains they
increase foot blood flow and exercise capacity very rapidly.  However, while
resting foot blood flow increases to 100%, exercise capacity remains below 70% of
control mice without occlusion of the femoral artery.  Foot blood flow of sv129
mice was slightly less after four weeks when compared to C57Bl/6 mice.  Exercise
capacity was very similar after four weeks.  Again, resting foot blood flow
recovered to almost 100% but exercise capacity remained below 70%.  Finally,
Balb/C mice showed the worst recovery in foot blood flow (51%) as well as in
exercise capacity (48%).
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